follow disappoint biotech stock hope
record number nme approv remain optimist innov
compani creat sharehold valu develop success product
certain headwind polit rhetor drug price plenti financ
nonetheless biotech busi model remain intact
blockbust product want found think sector overal
struggl past year due rel drought success innov
new drug product launch consist handili beat expect
nme approv ever think biotech busi
model broken hand new product dramat chang impress new
product cycl could major impact stock see product need
get solid start
year biopharma see continu trend biotech
skeptic bolu activ despit fast start year recent sell-
make valuat attract could acquir justifi pay
attract asset rather like least partial constrain
limit avail good strateg asset right stage develop surround
right team
larg cap perform valuat modest larg cap prove
defens portion sector market remain
volatil would like increasingli prefer also degre generalist rotat
biotech like benefit name remain dubiou larg cap
fundament think smid cap biotech offer higher potenti intermedi
long term return invest
smid cap outperform think recal time
mani innov late-stag product-ori compani flush cash
control destini moreov help reset valuat despit
higher risk profil often unproven manag team believ provid
better prospect attract return
group anticip meaning drug price legisl
expect headlin propos legisl attack continu democrat took control
congress jan subpoena power reduc pharmaceut price
appear one area trump administr democrat
agre rhetor like increas presidenti elect approach
suppli new paper subsid banner year biotech capit
market activ invest banker may applaud view buysid
much temper mani blame suppli new paper reduc demand overal
suggest play part biotech lacklust perform mani investor say
littl interest particip financ earli nonetheless
remain much demand corpor capit shortag privat
compani hope ipo moreov fund need alreadi public compani
substanti estim compani cowen univers enter less
two year cash
could go wrong risk biotech perform includ new product
launch balanc disappoint continu reset valuat broad
pleas see page report import disclosur
market biotech specif excess financ activ drug safeti scandal real
perceiv threat drug pricing/reimburs
expect financi perform idiosyncrat compani howev tend
exhibit season strength order pattern major pre-announc
line better hand demand trend remain lacklust sever
franchis hcv g-csf report season investor
look evid larg cap capabl healthi growth host
newer product launch progress well tegsedi onpattro
dupix libtayo
cowen biotech prefer invest smid cap compani innov late-
stage product address major unmet medic need smid cap believ
potenti strong includ gwph
myov among larg cap think
could lead group base upon prospect late-stag pipelin drive
superior earn growth reason valuat
arri estim gwph estim stub cowen compani consensu thomson reuter bloomberg compani compil
companytickeranalystreport datepric opinionacadiaacadbarallik feb depress clinic meaning expect detail phase design quarter achaogenakaoshibutaniearli share regard compani go-forward outlook separ zemdri on-going discuss updat regard anticip data includ rational combin plan stoke interest alexionalxnnadeaufebruari optimist rapid convers lessen concern competit reinvigor investor expect investor need greater visibl growth driver share meaning inflect alnylamalnybarallik earli februari prescript trend number franchis neupogen/neulasta epogen nplate track somewhat consensu offset track behind aranesp prolia xgeva therefor think consensu total revenu estim achiev expect cost control yield ep least line amicusfoldbarallik earli februari ww launch remain strong continu think us commerci opportun larger consensu investor interest remain pomp program pivot trial on-going potenti nda file gt program also advanc follow-up data expect march data studi diabet peripher neuropathi expect first half aptx present compel interim data on-going exploratori trial fibromyalgia present complet data aptx plan start fibromyalgia trial array biopharmaarryshibutaniearli anticip continu solid execut mektovi/braftovi commerci launch visibl timelin braf-mut particular first-lin anchor studi provid key catalyst see attract risk/reward given low expect initi combo data mss audent pharmaboldbarallik march program updat crigler-najjar due quarter bold believ resolv issu pomp program track file ind given consist clinic result expect clean regulatori path forward xlmtm bold give detail regulatori updat program potenti aducanumab interim look nadeaumid-l prospect pipelin program val rox vosoritid continu think core mid cap hold celgenecelgnadeaujanuari control trade focu anyth potenti disrupt deal notabl ip disput dynavaxdvaxnadeauearli pivot front-lin melanoma trial emerg biosolutionsebspeakerl follow contract well driver newli acquir product narcan vaxchora vivotif exelixisexelpeakerl compel gilead sciencesgildnadeaufebruari overallweexpectaquarteratleastinlinewithconsensu trendsforboththehivandhcvfranchisesseemtobetrackingjustaboveourestimateandconsensu investorswillcontinuetolookforsignsthattroughearningsar final sight clear understand new manag strategi reinvigor growth gw pharmaceuticalsgwphnadeaulik earli nonetheless investor keen understand quickli epidiolex adopt cowen
cowen compani consensu thomson reuter bloomberg compani compil
companytickeranalystreport datepric opinionheronhrtxpeakerl see high liklihood approv follow launch immunomedicsnadeauearli approv either around sacituzumab pdufa date remain top-smid cap pick insmedinsmbarallik earli februari consensu investor focu addit color around launch metric driver favor inclin toward broad unappreci pipelin intercepticptbarallik earli februari sale pbc stabil iqvia script suggest beat investor focu squar ocaliva nash program expect read phase regener data remain bullish data readout view binari occur la jolla decemb fda approv investor debat whether ever meaning expand salesforc educ td-interfac physician pacirapcrxpeakerl compani provid guidanc earn call estim sale pdl biopharmapdlinadeaul february/earli tekturnaandglumetzasalesarethelargestdriversofrevenu andweanticipatestrengthfromglumetzawillcompensateforsoftnessintekturna pdlseeksspec pharmaproduct withtekturnaandglumetzafacinggener competit think good acquisit necessari creat meaning sharehold valu portolaptlanadeaul andexxa est like hope andexxa ramp drive out-performance ptc therapeuticsptctbarallik novemb guidanc hope approv risdiplam given part result firefish sunfish studi type sma respect suffici file nda/maa february/earli initi eu launch potenti partner could reassur financ risk remain overhang radiusrdusshibutanil develop elacestr view underpin potenti posit inflect stock regeneronregnnadeauearli februari weexpectquarterlyfinancialstocomeinlinetojustaboveconsensu preannouncedu eyleasaleswerejustoverconsensusestimateswhilescripsforpraluentanddupixentaretrackingaboveconsensu weexpectthecallto highlight compani earlier stage oncolog effort libtayo launch sagesagebaralfeb read safeti durabl mdd opportun data due sangamosgmobaralearli top-lin releas last septemb follow-up mps-ii data expect world feb orlando sareptabarallik first biopsi data program major catalyst stock seattl focus chl mtcl sale ramp spark expect near mid-year phase studi set begin dose cowen
cowen compani consensu thomson reuter bloomberg compani compil
disappoint year biotech stock nasdaq biotechnolog index
nbi year small cap heavi xbi fell
under-perform broader market djia sever factor
contribut sector under-perform includ high beta natur
biotech declin broad market larg number biotech equiti offer
rais follow-on ipo year figur biocenturi
aggress valuat smid cap start continu
concern surround drug price larg cap suspend price increas mid
year increas reimburs headwind mix clinic regulatori news
introduct brought back short launch mindset
tsro continu mediocr fundament among
larg cap factor pressur stock sector fair say
sentiment toward group among generalist investor remain rel poor
nonetheless opinion busi model biotechnolog remain intact
gener dont see major chang way drug discov
develop approv sold individu biotechnolog stock fail meet
expect like perform poorli innov develop new product
continu creat long term sharehold valu fact despit perform
sector data point suggest fundament
biotech sound exampl fda approv nme
year sinc fda began track approv number pipelin remain full
mani compani appli newer technolog platform gene therapi cell
therapi rnai address major unmet need addit cowen washington
research group anticip legisl meaning impact
way biopharmaceut price fact part drug price
grown high past year return associ success new
drug treat unmet medic may higher ever
cowen stand outlook biotech overal view
modestli posit think reset valuat healthi particularli
xbi remain optimist prospect
compani particular smaller innov compani creat sharehold
valu via busi model believ normal year biotech might
provid sharehold return roughli line industri growth rate
chang everi year often dramat consequ stock price
perform investor sentiment sentiment toward biotech enter mix
companytickeranalystreport datepric opinionultragenyxrarebarallik earli februari produc encourag result recent unit therapeuticsuthrshibutanil top-lin yet-to-be-rev detail matter seem unlik materi earn iii follow fda file remain top pick best industry-high revenu growth cowen
tent specialist discourag shell-shock depreci
quick dramat close end year generalist
larg disinterest possibl sentiment could swing either direct
next month handicap sentiment move difficult
assess fundament factor could major impact sentiment
address take bit luck stabil broad market
sentiment could swing somewhat favor provid tailwind
stock though admittedli benefit difficult call
blockbust product want think sector particularli larg cap
struggl past year mostli due singl root caus rel drought
success innov new drug follow terrif cycl new blockbust
launch time-frame solvaldi tecfidera xtandi imbruvica pomalyst
otezla kyproli industri wit limit success particular rel
product launch past year consist handili beat investor
expect ingrezza estim revis recent launch tend
moreov number product launch
appear capabl achiev blockbust statu particularli larg cap space
small aimovig biktarvi dupix yescarta symdeko rel current scale
biotech industri obviou ramif outlook growth
challeng
dearth success new product launch past year
mean biotech busi model broken rather histori indic pipelin
product ebb flow even hand new product dramat
alter percept toward group consid key environment factor
industri face see noth dampen industri chanc
potenti success fact nme approv industri
shortag opportun gener revenu growth creat sharehold valu
given reward associ success still high investor expect
quit modest new product cycl could major impact stock cours
gaug whether year success launch difficult predict
gw epidiolex insm arikayc regn libtayo regn dupix asthma
need get solid start order investor remain optimist new
product cycl begun
 rescu larg biopharma compani gener cash rich pipelin
poor need bring innov new product hous therefor would
appear shortag need acquisit fact two major acquisit
announc first week celg loxo investor like debat
whether long-anticip wave industri consolid begun particular
bull suggest declin biotech valuat begun acceler pace
subscrib view larg biopharma compani increasingli depend
upon smaller compani innov expect remain persist theme
biotech benefit smid cap investor mostli expens larg cap
nonetheless despit two earli deal skeptic year
except deal activ reason averag year deal
probabl littl valuat industri contact suggest deal
rare scuttl simpli target valuat high rather reason
averag year probabl factor like
find right strateg asset right stage develop surround
right team histor analys biotech see suggest transact
happen buyer seller reach align mani issu near perfect
storm recur theme come wave
nonetheless could still see activ exclud
eu transact rel quiet period
much wors rhetor drug price get notabl
polit rhetor drug price percept modifi behavior
biopharmaceut compani biotech firm continu practic
take substanti price increas seemingli undet populist
critic identifi discret biotech price increas univers enact
januari april howev dynam chang
dramat follow unveil presid trump drug price plan
subsequ comment secretari human servic impli
name shame tactic would employ compani rais price
identifi price increas enact april juli well
price increas identifi lack signific
price action continu price increas well
taken taken fact
number biotech celg pledg rais price
other commit rais price beyond cpi
highlight value-bas reimburs agreement payor industri
effort self-polic keep annual drug price increas point finger
drug suppli chain highlight valu innov new product gene
therapi appear temper populist anger bit
cowen washington research group anticip legisl
meaning impact way biopharmaceut price
expect headlin propos legisl attack continu particular
democrat took control congress januari subpoena power
could use shine light industri price practic moreov reduc
pharmaceut price appear one area trump
administr democrat agre rhetor around drug price like increas
presidenti elect draw closer infam hillari
clinton drug price tweet spark sell biotech stock occur
septemb approxim month elect therefor
like point biopharma industri back
spotlight defens
suppli new paper begin subsid banner year biotech
capit market activ rais follow-on ipo accord
biocenturi invest banker may applaud view buysid
much temper mani blame suppli new paper reduc demand
overal suggest play part biotech lacklust perform
particular follow notabl ipo perceiv aggress valu
quickli broke deal price mood toward ipo sunk disinterest
toward aggriev anger suspect investor choosi
next sever month select support compani strong fundament
pedigre manag attract valuat nonetheless remain much
demand corpor equiti financ shortag privat
compani hope ipo moreov fund need alreadi
public compani substanti estim compani cowen coverag
univers enter less two year cash balanc sheet
normal environ would expect access equiti market
take big cap larg cap celg
averag perform modestli outperform
nbi xbi two best perform
celg worst case histor larg cap
defens market reason valuat good visibl
near term earn larg cap less suscept swing investor
sentiment small cap demonstr hold better
market sell off moreov generalist re-engag biotech would like
start invest larg cap addit although larg cap fundament tend
chang glacial pace sentiment swing occur much rapidli
provid plenti trade opportun larg cap
nonetheless overal larg cap continu busi face challeng
enthral fundament investor view mani larg cap
compani wrong side two key theme product
discuss henc prefer mid cap name despit higher risk profil
mid cap portion sector compani attract
mixtur innov pipelin de-risk develop candid near-term
mileston valuat path revenu growth liquid
cowen compani
whether interest larg cap mid cap small cap like featur
plenti mileston event generalist part sidelin
fund flow somewhat limit environ foster stock pick els
good diverg individu stock perform cowen biotech team
believ follow stock best chanc outperform peer
 confid nuplazid nrx grow back level drive
overal sale growth meet revis guidanc continu
growth clariti data nuplazid adjunct depress highli
clinic meaning kol underappreci street see mdd
blockbust opportun expect detail phase design see
increas investor appeal approach drp trial interim look
adjunct schizophrenia data due end year
 agio premier smid-cap compani focus precis oncolog
metabol diseas look demonstr strong commerci execut
amidst competit concern improv visibl expand front-lin
opportun idh-inhibitor aml franchis coupl deliveri data
updat uniqu high-potenti pipelin opportun mitapivat pk defici
mtap-delet tumor drive out-performance
 compani lead ms franchis appear stabl weather
competit storm roch ocrevu meanwhil pipelin begin
show sign potenti believ stock price-to-earnings multipl gain support
aducanumab pivot readout alzheim diseas earli approach
 galafold ww launch remain strong continu think us
commerci opportun remark strong launch larger
consensu investor interest remain pomp ert program pivot trial
on-going potenti nda file newli in-licens orphan gt program
also advanc continu matur follow-up data
program expect gene therapi
program expect complet enrol end year
gwph epidiolex launch dravet lennox gastaut syndrom
expect rapidli adopt standard therapi estim achiev
world-wide sale expect gw stock outperform market
epidiolex commerci launch ramp
 cinv franchis look strong despit aloxi gener sustol cinvanti
well posit reimburs asp plu spread compani nda
accept assign pdufa date april see high
probabl approv follow strong uptak driven superior
immediate-releas bupivacain doc desir reduc opioid prescrib
 lead candid sacituzumab govitecan produc compel ph ii data
metastat tripl neg breast cancer mtnbc januari pdufa
expect approv launch consult expect rapidli
incorpor standard care dcf-base price target
jakafi continu grow steadili approv product cash support
expect investor gain greater confid pipelin itacitinib
inhibitor gvhd pemigatinib fgfr inhibitor bladder cancer
cholangiocarcinoma topic ruxolitinib inhibitor atop dermat
vitiligo gener multipl phase ii/iii dataset
 arikayc recent receiv acceler approv us base posit
phase cultur convers data refractori ntm patient pre-announce
encourag extrem strong arikayc first launch quarter handili beat
consensu buy-sid expect littl indic slow
investor focu addit color launch metric forward ramp
rest year think continu exceed expect
 mirati uniqu posit captur signific
opportun within oncolog includ nsclc patient receiv immuno-
oncolog regimen post checkpoint inhibitor set anticip investor
attent heighten markedli anticip initi clinic data compani
kra inhibitor recognit compani strateg valu support
myov myovant lead candid relugolix potent once-daili gnrh antagonist
phase program uterin fibroid endometriosi prostat cancer top-lin
data expect think relugolix peak potenti
base dcf analysi myovant under-valued relugolix
 neurocrin inhibitor ingrezza fda approv tardiv dyskinesia
april handili beat expect first seven quarter orilissa
elagolix partial gnrh antagonist succeed pivot program
endometriosi uterin fibroid fda approv endometriosi juli
 remain best idea despit januari volatil compani
execut remark turnaround matur vertic integr smid cap
biotech durabl oligo base busi deep pipelin gene therapi
program orphan neuromuscular diseas key clinic regulatori catalyst
year includ lgmd data could mayb new potenti
pivot gene therapi trial start end expect deep
diversifi yet commerci concentr pipelin continu drive valu
near mid long term
 elzonri recent approv broad label bpdcn first
target therapi weve receiv posit kol feedback elzonri
view revenu estim conserv beyond us see
high probabl eu approv potenti partnership follow
 lead candid non-absorb polym remov acid
gastrointestin tract develop treatment metabol acidosi
sale potenti succeed high statist signific
pivot phase trial think investor interest increas
file fda approv launch approach
 model assum cystic fibrosi patient one vertex
therapi drive sale project industry-
high revenu ep compound-annual-growth-rate period impli
fastest grow larg cap period maintain price target
pain quarter biotech stock market gener larg
cap-weight nasdaq biotechnolog index nbi declin smid cap
weight amex biotechnolog index btk fell small cap heavi xbi
declin comparison djia declin fell
nasdaq composit biotech stock enter quarter
much momentum btk set all-tim close high septemb biotech
demonstr high beta natur octob sold aggress concern
trade war rise interest rate deceler growth pressur broad stock
market rapid steep depreci came final quarter year
left specialist dismay generalist larg uninterest biotech
shown sign return perhap posit thing
end biotech bounc start new year
cowen compani thomson
overal banner year biotech ipo specialist investor continu
desir innov platform novel product nonetheless number
ipo broke deal price sour investor mood toward new offer key question
whether suppli biotech ipo outstrip demand earli
end investor shell shock depreci quick
dramat close end year sentiment wors
rememb last five year fact mani investor develop bear
market mindset see cowen latest thermomet fortun
start well nbi btk xbi christma eve
low aid early-januari announc acquisit celg loxo
perform improv specialist increasingli engag hope
opportun profit invest
typic correct interest shift somewhat high fli smid
cap toward larg cap investor becam conserv reason
valuat attract liquid good visibl near-term revenu earn
larg cap segment perceiv safer held somewhat better
smaller stock market declin moreov segment notabl
pipelin success help improv percept includ fda approv
regn dupix asthma alxn ultomiri pnh well releas
posit data vrtx tripl regimen cystic fibrosi
said specialist enthral larg cap revenu growth pipelin
fundament segment view place temporari trade rather
long-term buy-and-hold invest investor seek rel safeti
larger name posit neg develop biotech stock
market cap excess lead market cap
group nonetheless stock coverag cowen market cap
fell quarter top perform buoy
solid financi perform sector highest dividend yield regeneron
benefit increas optim follow fda approv libtayo
cscc late dupix asthma earli
support washed-out valuat increas optim pipelin
laggard gilead hurt continu declin hcv franchis celg
worri revlimid longev persist suffer
persist concern competit franchis
though mid cap stock continu benefit view compani
innov growth orient larger cap peer began investor
worri valuat gotten bit stretch segment
suscept correct moreov typic sell-off posit develop
reward modestli neg surpris punish harsh
declin group mid cap stock cowen univers defin stock
market cap declin stock end
stock price higher began declin best perform
tsro announc would acquir gsk market perform
steve scala decemb top perform includ argx
benefit either favor pipelin updat
better expect perform market product underperform includ
clinic setback commerci
disappoint simpli gave back gain follow
strong perform earlier year gwph
averag perform small cap univers market cap compani
total lag two group third quarter row
averag declin sever factor pressur small cap includ percept
riski binari rel lack liquid high beta natur
dilut demand due larg number financ well compani specif
pipelin failur compani demonstr pipelin progress reward
though punish unfavor clinic updat
and/or wane sentiment far harsher reward gener clsd
snss tril akao fact
small cap coverag appreci lost
valu
one biggest issu larg cap biotech mix financi perform
cours earn driven biotech post solid
spectacular result futur financi project adjust often
combin percept pipelin lacklust investor grown
concern best day revenu growth earn surpris past
investor look sign larg cap re-establish track
record consist financi perform beat rais common
disappoint cut chart depict consensu
ep expect fluctuat time includ search sign
improv visibl group competit categori gild
hcv biib ms celg otezla amgn enbrel g-csf better read
prospect newer drug amgn aimovig repatha alxn ultomiri pnh
soliri gmg gild yescarta regn dupix praluent biib/ionss
spinraza incy/lli olumi nbix/abbv orilissa
thomson cowen compani
meanwhil smid cap investor pay close attent plethora new drug
rare crysvita rduss tymlo stml elzonri
expect financi perform fairli idiosyncrat compani howev
macro trend worth consid favor side biotech sale
get boost price dynam favor earli year
mani franchis benefit price hike taken season
strength order pattern
howev prescript trend remain lacklust sever blockbust franchis mani
compani elect freez price late earli price unlik
tailwind q/q dollar continu strengthen mani major currenc
thu far biotech financi perform solid celg
pre-announc essenti in-lin revenu
exceed expect launch well ahead
expect first quarter market disappoint
compani believ like post sale earn excess
consensu includ compani exhibit
sign struggl rel consensu includ akao compani
anticip report financi less line expect includ
demand trend look like mix bag sever blockbust franchis matur
point sale declin although instanc iqvia data may
wholli accur prescrib trend key product includ gild hcv
busi biib ms franchis amgn g-csf enbrel lacklust
fortun biotech appear midst new product cycl fda
approv nme modern era record follow given biotech
need innov new product financi metric manag commentari
surround new product launch close scrutin mani new
product especi oncolog loxo viktravi regn libtayo stml
elzonri orphan categori alni onpattro bmrn palynziq fold galafold
gwph epidiolex insm arikayc alxn ultomiri launch outlook appear
biotech becom conserv price action
biotech firm continu practic take substanti price increas
seemingli undet populist critic identifi discret biotech price
increas univers enact januari april howev
dynam seem chang dramat follow unveil
presid trump drug price plan subsequ comment secretari
human servic impli name shame tactic would
employ compani rais price identifi price increas
enact april juli well price increas identifi
lack signific price action continu
price increas well taken
well univers fact number larger biotech
celg pledg rais price level nois
attent increas clear debat drug price stay
investor anticip headlin progress
pricerx cowen compani
sale season strong investor becom accustom
season strong ship pattern factor might contribut higher
anticip sale weaker expect includ wholesal stock
trend ahead holiday medicar patient shoebox drug
januari reset donut hole howev compani also known ramp
spend keep ep upsid check effort keep dri earn
powder new year
fx headwind compani ex-u exposur valu
dollar strengthen rel major foreign currenc q/q basi dollar
appreci versu british pound canadian dollar chines yuan
euro japanes yen q/q dollar weaken
brazilian q/q
mani compani attempt hedg partial hedg exposur expect
strengthen dollar translat somewhat lower ex-u revenu lower ex-
 oper cost compani signific foreign sale
cowen compani compani sec file
last quarter sale deriv
guidanc
cowen compani consensu thomson reuter
acadia nuplazid pimavanserin approv treatment parkinson
diseas psychosi pdp launch commerci nuplazid first
approv treatment pdp pois fill clear unmet medic need
diseas base annual price per patient us predict good
reimburs see peak us sale peak ww sale
upon eu approv acadia multipl on-going trial pimavanserin follow-on
indic includ schizophrenia major depress disord phase harmoni
trial dementia-rel psychosi drp
look long-term linear growth nuplazid step
near term return nuplazid growth safeti overhang lift fda
clear thorough review report nuplazid deaths/sa
faer databas fda conclud new risk associ
nuplazid post conclus statement websit came
surpris us base kol discuss well review fda
analysi pimavanserin adcomm care adjud
clinic trial death think public statement go long way
allay patient/caretak safeti concern like boost nuplazid back
growth soon think formal fda updat directli address
overhang remind market feedback suggest stall
prescript growth driven larg consum caretak hesit
driven splashi lay media report rather clinician concern
align kol check indic unanim believ
drug safe like safer antipsychot altern
continu expect long-term linear growth nuplazid prescrib
patient rebuild confid dust settl nuplazid safeti
estim nuplazid sale compar consensu
estim report nuplazid revenu
estim slightli consensu
compani revis net product revenu guidanc rang
increas reflect increas nuplazid
cowen compani
present top-line data phase clariti trial pimavanserin
adjunct mdd clariti phase random double-blind
placebo-control studi major depress disord mdd evalu
efficaci pimavanserin adjunct therapi ssri snri minim
placebo effect conduct trial use spcd sequenti parallel
comparison design rel novel structur psych conduct trial
two sequenti stage stage studi particip random
placebo arm treatment arm mg pimavanserin five week
note unusu high number patient origin assign pbo
stage five week patient deem pbo non-respond
re-random either placebo treatment anoth five
week pimavanserin met primari endpoint studi equal weight
averag stage stage valu effect
particularli strong stage reduct score
clinic meaning point pbo treatment
remark effect size howev stage pimavanserin
show improv score one would expect
see better efficaci stage trial invers seen
find pimavanserin statist strength consist
primari secondari endpoint stage data consist even
sometim echo stage convinc real efficaci signal adjunct
depress even convinc discuss
kol argu stage result highli credibl hold
weight stage data given experiment design protocol
patient number rare see unanim agreement kol drug
efficaci murki conflict phase data view encourag
sign pimavanserin develop adjunct depress look
forward phase design detail specif power trial
believ trial well design power success
clariti data remain track meet fda shortli
phase design includ spcd stage start trial
harmoni phase trial pimavanserin drp initi
primari endpoint averag time relaps pimavanserin
placebo harmoni design relaps prevent trial histor
high rate success durat random treatment
lead rel low placebo-medi relaps prevent rate
would expect emerg first week treatment
sustain past week treatment note harmoni track
us site run intern site activ also
progress nice provid enrol updat harmoni
estim timelin prospect interim data analysi plan
requir event final analysi expect final result around
earli year trial start interim result
appear reason confid chanc success interim cite
previou interim analysi success relaps prevent studi
phase enhanc trial pimavanserin adjunct treatment
schizophrenia due read phase advanc trial
pimavanserin schizophrenia neg symptom remain on-going data
anticip late
cowen compani consensu thomson
zemdri sale estim
consensu expect initi
launch ramp gradual
akao total revenu estim
consensu
estim ep
earn summari expect earn call center zemdri
launch remain mission-crit compani follow juli
restructur announc on-going strateg process latter
natur could unfortun bit frustrat topic given customari limit
term manag posit share given tradit legal
constraint process continu look manag commentari
regard regulatori progress potenti indic complic urinari
infect cuti bloodstream infect bsi eu submit
octob whether remain potenti bsi indic us
complet respons letter potenti bsi indic receiv fda approv
zemdri cuti
zemdri zemdri sale estim compar consensu
estim zemdri launch began juli partial
quarter sale report report zemdri revenu partial quarter
comparison context note allergan launch avycaz
late april report sale quarter conserv
estim zemdri stem part broader competit landscap multipl
brand antibiot includ avycaz vabomer xerava zemdri compet
patient multidrug-resist gram-neg infect
includ caus carbapenem-resist enterobacteriacea would also
logic surmis on-going restructur effort manag
conced encroach abil press aggress launch effort
might otherwis hope weigh initi launch momentum
vabomer zemdri grant new technolog add-on payment
center medicar medicaid servic provid hospit
payment beyond standard-of-car diagnosis-rel group drg reimburs
zemdri program provid cost zemdri
period year effect octob zemdri
sale estim consensu estim
c-scape oral combin ceftibuten approv third-gener
cephalosporin clavulan approv beta-lactamas inhibitor achaogen
develop drug infect caus bacteria produc extended-
spectrum beta-lactamas esbl addit phase clinic pk work would
requir phase trial cuti could design achaogen previous note
look updat compani commit develop
invest thesi zemdri plazomicin achaogen novel modifi aminoglycosid
antibiot think signific clinic promis treatment infect
caus antibiotic-resist gram-neg strain includ drug shown
impress activ number seriou infect type caus differ resist
gram-neg pathogen corpor restructur on-going manag
squar focus execut upon zemdri launch develop strategi
support compani financ need
burn financ strategi support restructur compani
zemdri sale launch metric intermediate-term outlook look
tangibl metric relat launch includ key account coverag
regulatori updat cuti bsi eu potenti
respons bsi indic us
c-scape updat includ whether phase asset factor
on-going strateg discuss
bloomberg cowen compani
last week guid ampyra sale
impli least
revenu nonetheless ampyra sale less
focu given rapid eros gener
near-term financi less focu
estim assum rapid declin
consensu may reason
provid inbrija guidanc
inbrija success import
determin acor stock perform
though loss anticip investor look
sign acor cash balanc
suffici fund oper back
reiter opex guidanc provid initi opex guidanc therefor
much suspens acorda financi report remov moreov
ampyra rapid declin follow launch gener septemb short term
financi less focu investor inbrija immin launch inbrija
approv fda decemb launch follow initi
market prepar physician educ acorda field team investor
keen learn inbrija price launch time on-going discuss
payor continu think inbrija alon support valu
therefor under-valued potenti
ampyra sale earli januari acorda announc preliminari estim full
year ampyra sale ahead prior guidanc
impli least ampyra sale adjust estim reflect
guidanc estim increas impli
non-gaap op ex guidanc sg
model consist guidanc project ep
non- ep consensu ep non-
gaap ep pre-announce element revenu
expens anticip major surpris ep
acorda guid cash greater base estim
model consist acor guidanc balanc suffici fund
oper profit nonetheless model suggest acor cash balanc
would get without addit financ therefor
would much room error inbrija sale ramp quickli
project model assum rais provid
financi cushion
iqvia cowen compani
septemb acorda lost appeal restor ampyra invalid
patent would protect exclus appeal
court upheld prior rule district court invalid ampyra patent
decis clear way
launch gener version dalfampridin
sinc appeal court rule five dalfampridin gener launch
author gener accord aurobindo ascend hikma wac discount
respect brand ampyra think possibl
three gener compani could launch acorda receiv eight
paragraph iv certif notic believ eight compani share co-
follow gener launch ampyra prescript declin rapidli
week christma holiday ampyra trx approxim
run rate august first gener launch moverov gener
launch wac discount would appear price small fraction
brand
gener launch deep discount ampyra prescript rapidli
declin therefor expect precipit declin ampyra revenu well
ampyra gener revenu mean run
rate assum declin price ampyra would repres market
would divid among player ampyra estim
manag note outlook ampyra uncertain given launch
gener longer provid revenu guidanc product ampyra
longer central invest case acorda though mean financ
compani therefor think futur sale peripher interest investor
approv inbrija nda ahead januari pdufa inbrija inhal
powder levodopa indic intermitt treatment episod
patient parkinson diseas treat carbidopa/levodopa
requir recommend lung function monitor contraind
use morn episod contraind patient
taken nonselect mao inhibitor within week inbrija dose two
capsul need five episod per day acorda launch
inbrija field team complet initi market prepar physician
educ acorda note retain vast major ampyra sale
market team despit recent launch dalfampridin gener inbrija price
disclos time launch inbrija distribut network
specialti pharmaci therefor manag uncertain whether publicli
avail prescript data accur acorda initi market focu
movement disord center treat vast major parkinson patient acorda
estim neurologist account prescript volum make
volum acorda expect sampl inbrija via free starter pack dose
evalu whether type sampl use spur use
inbrija approv major mileston acorda put compani path
toward return profit investor concern inbrija approv
could delay inhal drug/devic combo nonpulmonari diseas
howev inbrija approv came end first review cycl ahead
earli pdufa date think inbrija label favor fact nearli best case
scenario broad treatment episod requir lung
monitor restrict use morn episod one
contraind furthermor limit evid use mao inhibit
parkinson believ contraind littl deter elig patient
initi therapi therefor label would seem element would
expect handicap inbrija launch
continu think inbrija address unmet need expert estim
parkinson patient experi episod half-lif current
avail treatment minut storag releas capac also
diminish time episod occur frequent problem worsen
diseas progress first year diseas onset avail therapi work
well patient year diseas onset howev symptom re-emerg within
hour post dose consist problem consult observ among
parkinson patient group late-stag patient need viabl treatment
physician survey prior confer optimist
inbrija use physician specialist survey major found inbrija
clinic efficaci moder major clinic signific
clinician investor view inbrija clinic benefit
cowen compani confer
panelist note pulmonari rout drug deliveri rapid drug
make sens way close gap dose one panelist anticip inbrija
tri major patient need new treatment option
familiar effect levodopa compar sublingu strip
panelist believ inbrija superior reliabl safeti one panelist note
mechan action independ carbidopa posit concern
nausea hypotens make less comfort allow patient dose
medic safe home physician specialist survey anticip
treat patient episod inbrija three year time
cowen compani confer
anticip much quarterli call focu acorda physician educ
program convers payor price time offici launch
acorda file sinc valid decis approv
ema expect
model assum patient use dose inbrija per day dose per
day day per month scrip impli approxim per
dose per patient per year estim parkinson
patient experi episod project
inbrija therapi inbrija estim
acorda expect provid inbrija sale guidanc provid
metric total new prescript uniqu prescrib manag care
access launch progress
guidanc non-gaap expens non-gaap sg
expens adjust estim reflect guidanc
non-gaap ep estim
thesi sever dalfampridin gener launch signific discount
expect ampyra revenu declin rapidli howev continu think
acorda under-valued asset specif inbrija inhal l-
dopa inbrija approv fda decemb review
ema decis expect acorda launch inbrija
field team complet initi market prepar physician educ
consult impress inbrija profil anticip wide use
parkinson diseas patient experi episod
project inbrija achiev revenu grow
look launch inbrija concomit price announc
potenti approv ema inbrija possibl out-licens non-cor
candid updat pipelin program
idhifa royalti estim slightli
royalti rate consensu estim set celg analyst
celg consensu
tibsovo sale estim
consensu estim
total revenu estim
conserv rel consensu estim
ep primari near-term focu investor
agio cowen compani consensu thomson idhifa use celg analyst consensu
earn summari look earn updat focu first full quarter
sale compani wholli own tibsovo launch shortli juli
approv conserv project consensu
estim idhifa look continu steadi growth
consensu estim expect gener royalti
rang beyond commerci result expect investor focu ag-
includ factor underpin plan time share initi clinic
data well basi select initi combin studi indic on-going
effort expand tibsovo label start snda monotherapi use
untreat patient aml look anticip
februari updat studi involv tibsovo azacitidin investor like
compar venclexta data progress pipelin effort
tibsovo sale juli fda approv tibsovo ivosidenib wholli own
inhibitor r/r aml prioriti review advanc
august pdufa date tibsovo develop follow path similar
idhifa enasidenib inhibitor lag month expect agio
execut tibsovo launch reflect benefit experi gain co-
commerci idhifa celgen agent expect
prescrib group oncologist
consensu tibsovo sale estim
conserv estim recal possibl
includ partial quarter tibsovo sale agio report sale continu
expect earli phase launch limit
extent third-parti prescript data extrapol manag
commentari regard commerci progress outlook consist
project tibsovo becom standard care r/r aml
approxim patient diagnos aml year
patient harbor mutat project ww tibsovo sale
exceed upcom look condit eu approv base
tibsovo submit ema decemb confirmatori
idhifa sale royalti august idhifa sold partnership
celgen gain full fda approv treatment adult
relapsed/refractori aml idhifa launch price
price increas januari follow
januari announc bristol-my squibb acquisit celgen agio
manag note anticip commerci structur
implic exist partnership celgen
consensu idhifa sale estim among celgen analyst
celgen book sale
respect agio record royalti
royalti rate consensu estim seem slightli low view base
q/q trend therefor estim royalti agio model idhifa
royalti climb anticip sale guidanc
launch matur agio receiv tier royalti ramp idhifa
sale expect idhifa becom standard care r/r aml
approxim patient diagnos aml year estim
harbor mutat
thesi agio fulli integr drug discoveri compani target
cancer orphan diseas metabol compani first commerci product
idhifa cancer partner celgen produc impress single-
agent activ r/r aml md patient garner full fda approv base
phase data idhifa launch look solid start agioss wholli own
tibsovo cancer follow idhifa footstep similarli
compel data r/r aml intrigu data select solid tumor tibsovo
approv r/r aml launch late juli think idhifa
tibsovo could gener idh-mut aml mitapivat thu
far demonstr solid proof-of-concept data pyruv kinas defici orphan
diseas pivot trial initi activate-t activ
pk defici repres potenti opportun agio enter clinic
evalu mtap-delet tumor potenti enorm opportun
could includ solid tumor
view agio premier smid-cap oncolog orphan diseas compani
expect pipelin commerci progress propel share higher
tibsovo expect sale launch metric outlook well
commentari label expans effort expect tibsovo
azacitidin studi updat februari
idhifa expect royalti outlook well commentari
continu execut acquisit celg
anticip initi inhibitor data patient mtap-
delet tumor look increment insight guid
compani develop strategi thu far includ basi begin
combin studi specif indic
pkr inhibitor potenti commentari progress enrol
pivot trial pk defici full enrol expect
dhodh inhibitor potenti updat time phase trial initi
expect plan program
cowen vs street consensu estim
alexion guidanc call soliri sale
suggest sale base disclos
number gmg patient soliri expect sale
exceed estim consensu
alexion guidanc call metabol sale
kanuma contribut suggest
strensiq sale
kanuma major disappoint littl visibl
if/when sale might becom meaning
consensu forecast revenu alexion guidanc
though like achiev base soliri upsid
guid soliri pnh patient convert
ultomiri end think rate convers
soliri ultomiri key determin alxn stock
perform
ep excl stock option expens non-cash tax cowen compani consensu bloomberg
report date monday februari open alexion host confer call
et us confer id
earn summari alexion underli soliri busi remain strong expect
continu underli sale growth driven new patient add pnh ahu gmg
consensu soliri sale estim call q/q growth
y/i growth last week disclos number gmg patient soliri grew
q/q base upsid gmg alon expect soliri beat
consensu despit strength alexion busi stock struggl
past year investor worri impact brand biosimilar
competit alexion complement franchis ultomiri approv
late decemb ahead februari pdufa alexion manag state
ambit convert least pnh patient soliri ultomiri
optimist rapid convers soliri use pnh
reinvigor investor interest
call discuss topic expect alexion confer call focu data
point earli day ultomiri launch base busi soliri gmg pnh
ahu competit posit alexion complement franchis rel
roch regeneron potenti biosimilar continu develop
ultomiri includ new formul indic alxn pipelin includ
soliri sale underli demand trend soliri appear strong alexion report
underli demand soliri grew y/i driven strong product sale
growth y/i net product sale japan y/i net product
sale major ahu pnh patient thought yet initi
treatment volum growth expect continu alongsid increas
awar surround diagnosi treatment condit alexion franchis
appear much room growth ahu pnh though ceil
well-defin nonetheless uptak gmg rapid expect major
driver growth
gmg launch show sign abat earli day soliriss launch gmg
alexion manag ambit first year revenu indic
outpac gener pnh ahu respect launchesan
ambiti target given soliriss paradigm-shift mechan action alexion
unfamiliar neurolog commun word manag state
earn call soliri launch gmg best yetand launch
continu steadi clip new patient start therapi month
soliri impress uptak gmg continu last week alexion report
gmg patient soliri end decemb
end septemb suggest patient start treatment month
patients/month assum averag annual cost
soliri gmg would impli sale soliri gmg ahead
soliri estim
q/q consensu q/q assum modest q/q growth
increas gmg patient soliri would appear enough drive upsid
estim consensu
moreov manag note pipelin patient come onto onesourc
consist suggest gmg launch show sign slow given
market size achr-mut refractori gmg patient broad prescrib base
depth prescript trend prescrib treat one
patient expect continu growth gmg sale addit though
discontinu rate seen pivot trial due non-respond
manag state real-world discontinu consider
soliri also approv gmg europ august japan decemb
though european launch mainli germani slow alexion manag
indic near-term commerci opportun japan promis
could add drug earli sale trajectori
alexion believ continu add pnh ahu patient steadi pace
diseas awar improv ceil sight pnh soliri launch
ten year ago yet alexion continu believ drug achiev
peak potenti alexion continu believ opportun serv ahu
patient larger pnh compani disclos number ahu
patient treat soliri exceed number pnh patient treat
 certain geographi substanti view ahu market
significantli larger peak drug launch gmg increasingli contribut
soliriss sale growth trajectori first year sinc launch exceed
pnh ahu respect
alexion patent protect soliri extend japan composition/
formul patent issu novemb three patent issu august
extend howev may european patent offic
reject new composit matter patent soliri alexion request oral
proceed set occur februari manag hope
three person panel instead review patent issu
biosimilar entri could occur around eu soliri sale
said seen biosimilar data commit
initi phase develop trial yet underway
alexion announc top-lin result phase prevent trial soliri
primari endpoint time first adjud on-trial relaps soliri reduc risk
relaps rel placebo week hr
patient soliri relaps free rel patient placebo
safeti profil consist seen previous soliri clinic trial real-
world use case meningococc infect alexion submit sbla
 prepar anticip launch regulatori file eu
japan plan submiss well
investor focu center market size competit posit soliri
nmosd given exist rel afford treatment option
horizon latter point roch phase data satralizumab
nmosd demonstr similar percentag relaps free patient week
pre-specifi cohort auto antibody-posit patient soliri trial
patient higher rate relaps baselin produc favor reduct
relaps risk rel placebo vs satralizumab satralizumab
abil produc compar efficaci sever patient popul unclear
prior check consult recogn acut need novel drug treat
patient refractori nmosd patient major risk
blind morbid mortal best estim might
patient develop geographi henc sever
patient subset might repres ww opportun larger opportun
soliri exist patient mostli complet control exist
therapi patient difficulti side effect toler
current medic estim anoth nmosd patient might fit
criteria consist estim half patient would
qualifi prevent trial subpopul could repres anoth
phase trial ultomiri nmosd set
ultomiri approv price discount decemb fda approv
ultomiri ravulizumab treatment adult patient paroxysm nocturn
hemoglobinuria pnh -- almost two month ahead februari pdufa
approv base ultomiri two phase trial treatment-na soliri
switch patient ultomiri achiev non-inferior endpoint label
contain surpris indic ultomiri administ load dose
follow mainten dose week base bodi weight patient
switch soliri ultomiri load dose administ two week
last soliri infus ultomiri price per vial six
infus per year mainten translat annual price approxim
american averag weight -- approxim discount
soliri howev year one patient continu initi ultomiri
annual price approxim inclus load dose access
treatment facilit alexion onesourc program provid
patient educ treatment support last week alexion disclos first
prescript ultomiri written alexion manag guid
convers least pnh patient ultomiri
regulatori submiss ultomiri accept review
eu japan
data ultomiri trial treatment-na adult adolesc ahu expect
phase trial gmg set initi earli
phase trial weekli subcutan formul ultomiri
alexion initi phase bridg studi use commerci avail devic
alexion plan file approv formul us eu
addit manufactur sbla higher concentr formul ultomiri
would reduc iv infus time approxim minut plan
final alexion develop subq version ultomiri
expect ultomiri rais bar competit hope rapid
convers pnh patient soliri ultomiri help allevi
investor concern long term competit franchis
particular ultomiri success lessen risk franchis soliri
biosimilar well rais bar futur brand competitor
nonetheless competit continu larg overhang alexion stock brand
competitor includ compani target pnh complement inhibit earlier
cascad apelliss sub phase develop pnh
aim differenti mode administr regeneron subq
move phase ii pnh durat action roche/chugai long-act
roche/chugai long-act subcutaneously-administ mab
develop treat pnh lag ultomiri coupl year
similar ultomiri especi term administr profil made key
potenti competitor fact convers investor mani view
biggest competit threat alexion long-term domin pnh
opinion data present suggest unlik
competit investig on-going phase i/ii trial
conduct part healthi volunt part treatment-nav pnh patient part
pnh patient previous treat soliri part initi phase data
present decemb year abstract includ interim data
part trial
chugai indic patient drug develop
antibodi last march part trial paus due two patient
experienc mild moder symptom immun mediat drug hypersensit
year abstract detail two patient total enrol
part experienc mild moder drug-target-drug complex dtdc mediat
reaction initi post-switch period day day respect
symptom similar serum sick dtdc compos soliri
abstract state expect occur switch soliri
due differ bind epitop two antibodi therefor patient
switch soliri like need washout period
phase i/ii treatment-nav pnh patient experienc reduct lactat
dehydrogenas ldh cytoplasm enzym baselin week
similar ldh reduct produc soliri ultomiri
howev mean ldh remain upper limit normal uln week
 uln rang uln level ldh compar seen
soliri pivot trial mean ldh uln day follow
produc ultomiri pivot ultomiri result mean ldh
 uln day follow pnh patient
switch soliri produc signific chang ldh week later
rel baselin though one patient mutat seen
pnh patient associ poor respons soliri normal ldh
importantli reduct ldh seen consist correl
reduct plasma total concentr increas g/ml
g/ml week patient part decreas g/ml g/ml
patient part total includ alon immun
complex ic must lower addit antibodi
reduc complement activ pnh patient suscept breakthrough
hemolysi knockdown incompletethough breakthrough hemolysi
due underli condit infect surgeri pregnanc bone marrow failur
extravascular hemolysi well abstract disclos two patient experienc
breakthrough hemolysi across part
deem unrel studi drug due infect atrial fibril respect
nonetheless rate somewhat higher seen pivot trial soliri
ultomiri soliri ultomiri though cross-trial
comparison limit rel small sampl size vs ultomiri
pivot soliri addit alexion distinguish episod
breakthrough hemolysi attribut studi drug vs
opinion data suggest fall short profil produc
ultomiri particular fact increas seen part
studi breakthrough hemolysi observ suggest us provok
immun complex prevent drug full effect put
patient increas risk breakthrough hemolysi patient number
small rate breakthrough hemolysi seen ultomiri
pivot trial moreov fact patient quit achiev ldh level
low ultomiri suggest might somewhat less potent addit
switch patient dtdc-mediat reaction similar serum
sick would seem switch patient onto safeti risk base
chugai comment abstract risk dtdc-mediat reaction appear
consequ differ epitop target soliris/ ultomiri
hard see dtdc could elimin risk like remain commerci
profil rais bar adopt appear us like use would
patient mutat respond well soliri
biosimilar front known compani conduct phase
clinic trial result releas indic
process initi phase
clinicaltri gov list on-going phase trial healthi volunt anoth
eculizumab biosimilar samsung bioepi set complet april
nonetheless either biosimilar program succeed phase trial
launch would follow ultomiri yearsat point expect major
patient convert soliri ultomiri
asfotas alfa enzym replac therapi treatment hypophosphatasia
approv japan europ strensiq experienc
one best ever orphan drug launch first full year
 market appear bright futur access expand addit
multipl sourc new patient expect strensiq achiev peak sale
alexion report strensiq sale y/i alexion
note growth driven continu uptak germani
estim q/q y/i consensu q/q
y/i expect continu penetr newli reimburs territori
drive revenu least line estim consensu
kanuma modest contributor alexion acquisit synageva primarili
base potenti kanuma enzym replac therapi ert
lysosom acid lipas defici lal-d drug launch germani octob
 januari sale fallen well short
expect synageva acquisit ill-conceiv
alexion tri improv patient identif program lal-d
refocus effort pediatrician role genet test alexion report
effort result patient identifi past quarter
howev sale kanuma modest show littl sign inflect
report revenu y/i expect sale essenti line
slightli consensu expect
septemb alexion announc enter agreement acquir
syntimmun lead candid neonat fc receptor fcrn antibodi
renam phase ib/iia develop warm
autoimmun hemolyt anemia waiha pemphigu vulgari pv pemphigu
result waiha phase i/ii anticip addit safeti
clinic endpoint on-going phase ib/iia hematocrit hemoglobin
measur weekli day alexion plan use hemoglobin
primari endpoint pivot waiha trial well expect initi phase
waiha later
demonstr abil reduc igg circul immun complex
cic alexion believ may effect rang igg-medi
autoimmun indic expect begin phase trial
second yet disclos indic well
though current dose iv clinic trial alexion look
extend dose interv improv conveni plan eventu examin
financi guidanc total revenu consensu estim
y/i estim y/i alexion manag tend guid
conserv feel comfort guidanc bracket estim
consensu nonetheless alexion track achiev y/i growth
sever reason expect acceler year ahead first patient
begin convert ultomiri initi load dose gener increas
revenu rel soliri though ultomiri price discount eventu advers
impact revenu first year launch switch patient gener
revenu second gmg launch continu ramp steep rate gain
invest thesi new manag done admir job stabil
compani grow soliri sale pnh ahu launch drug gmg
indic think favor financi outlook increas confid
compani abil convert patient ultomiri could posit share re-
rate investor gain confid growth durabl complement
look ultomiri phase trial ahu potenti data phase
trial subq possibl data ph i/ii waiha
initi phase ultomiri iv gmg
cowen compani consensu thomson
vivitrol sale estim
line consensu guidanc
lower end rang
aristada sale estim
line consensu
within guidanc rang
total revenu estim
line consensu
within guidanc rang
ep estim slightli
consensu within guidanc
rang
earn summari expect earn report focu vivitrol
aristada sale trend well upcom pipeline-rel event expect
vivitrol aristada look y/i growth rate observ larg
maintain vivitrol exceed aristada would help ensur
full-year guidanc met regard pipelin expect discuss plan
follow posit data nda submiss expect
progress includ timelin data readout
develop acceler view futur differ potenti
scenario recal novemb advisori committe review nda
posit safeti neg efficaci compani anticip
complet respons letter pdufa date jan regulatori timelin
partner nda accept expect
vivitrol project vivitrol sale q/q y/i
line consensu expect gross-to-net remain rel stabl
rang forecast price increas near futur full-
year forecast line manag earn
commentari sale toward lower end guidanc
rang expect manag continu provid updat number vivitrol
treatment program us recal grown start
start start
start given program repres consider variat term
unit volum similar metric manag typic refer
high-volum state rel indic forecast growth recent
complet legisl confirm increment financi resourc continu
direct toward treatment program broadli speak time amount
fund state level tough predict continu believ
vivitrol franchis posit underli fundament long-term basi
aristada expect continu solid in-lin perform estim
quarter sale q/q y/i consensu estim
aristada navig way past year within market
exist competitor amongst arguabl lot differenti
avail every-two-month dose regimen aristada increment
expand dose option schizophrenia patient beyond once-monthli every-six-
dispers approv formul help facilit initi therapi
allow physician fulli dose two month aristada treatment day one
faster-dissolv initio formul enabl therapeut drug level achiev
rapidli reduc need pre-inject oral supplement
point hurdl long-act inject adopt initio launch
result phase studi aristada initio invega sustenna
true head-to-head studi accord manag expect
aristada sale estim line consensu estim
within compani guidanc aristada wac increas
januari juli
novel broad-spectrum antipsychot compris olanzapin co-
formul samidorphan four-week efficaci studi
versu placebo acut schizophrenia patient olanzapin includ
compar arm studi enrol patient announc posit
top-lin data june arm show superior efficaci
compar placebo similar efficaci compar olanzapin panss score
endpoint second pivot trial six-month head-to-head studi
weight gain versu olanzapin adult schizophrenia
top-lin result announc novemb posit mean weight gain
reduc patient treat olanzapin
gain baselin bodi weight versu patient treat
phase weight studi young adult initi june
continu enrol nda submiss expect
expect pre-nda meet fda
conduct phase trial solid tumor patient assess
safeti efficaci novel select effector cell activ seca
design activ immunostimulatori receptor believ
overcom limit exist therapi activ
immunostimulatori immunosuppress receptor phase trial dose-
escal stage follow dose-expans stage two cohort
patient renal cell carcinoma patient melanoma recal
approv indic posit pharmacodynam result present
novemb hope show monotherapi efficaci data
phase trial also began evalu combin keytruda
septemb evalu subcutan formul
combin keytruda expect begin earli formul
expect go-forward formul efficaci compromis
formerli novel oral monomethyl fumar mmf molecul
develop multipl sclerosi novemb announc
global licens collabor agreement develop commerci
exclus world-wide licens commerci drug
alkerm entitl receiv mid-teen royalti world-wide net sale alkerm
elig receiv clinic regulatori mileston payment
maintain respons regulatori interact approv
respons commerci pay high-single-digit low-double-
digit tier royalti net sale product initi result
safeti studi patient present ectrim
confer octob continu show good gi toler low
rate discontinu due gi advers event head-to-head phase
studi gi toler versu tecfidera on-going
paid view preliminari data result
expect present pk bridg studi show
bioequival tecfidera requir studi elect studi
nda referenc tecfidera regulatori pathway
file decemb
combin opioid agonist buprenorphin samidorphan
compani proprietari opioid receptor antagonist develop adjunct
treatment major depress disord base neg outcom advisori
committe review novemb complet respons letter expect
januari pdufa date recal committe cast neg vote
whether avail data support favor benefit-risk profil support
approv result follow neg vote whether substanti evid
present support effect posit vote whether
safeti profil adequ character understand continu
conduct phase studi describ provid potenti path
attempt resubmiss nda though estim timelin
would like period earliest
invest thesi invest thesi share deriv compani
abil drive commerci success wholli own product portfolio vivitrol
aristada well compani abil success develop product late-
stage pipelin believ current level reflect investor skeptic regard
futur commerci prospect potenti
vivitrol growth meaning re-acceler howev believ vivitrol
aristada potenti grow substanti pipeline-rel
catalyst potenti gener signific upsid
vivitrol aristada sale outlook possibl guidanc
y/i growth rate approxim maintain
guidanc met look commentari aristada initio
affect aristada competit posit lai categori
plan follow posit data expect
differenti gener nda submiss expect
factor influenc pace develop oncolog
partner regulatori timelin nda accept
expect
committe vote novemb
alnylam guid revenu
cowen compani consensu thomson reuter
invest thesi think alnylam leader field rnai therapeut
compani built strong ip posit around construct deliveri
technolog taken modular liver-target approach drug develop
alnylam lead candid onpattro fka patisiran report strongli posit diseas
revers phase result treatment fap ttr amyloidosi receiv fda
ema approv fap august advanc pipelin program solid
driver long-term valu provid steadi catalyst flow
potenti launch next month recent interim analysi on-going
pivot phase trial givosiran acut intermitt porphyria aip report strong
result full outcom result expect like late quarter believ
alnylam announc soon initi roll nda pursu full approv
givosiran top-lin data phase atla program fitusiran hemophilia
 also expect mid-to-l also note upcom catalyst phase
primari hyperoxaluria
look addit onpattro launch metric givosiran data
patisiran approv august alnylam announc fda approv
onpattro patisiran treatment polyneuropathi hereditari
transthyretinmedi amyloidosi hattr adult eu approv follow soon
thereaft label specifi treatment adult hereditari transthyretin
amyloidosi hattr stage symptomat ambulatori without assist
stage requir assist ambul polyneuropathi
earli launch metric encouragingrec pre-announc onpattro revenu
encourag earli launch indic exceed
model estim like suggest faster payer approv process
binomi distribut except process current take month
infus center due committe approv requir coupl
week home infus alni expect binomi distribut
shrink committe discuss wrap vba detail disclos
alnylam note built premis apollo data
payer negoti slightli differ term
eap program continu feed signific number patient though believ
latest updat point slight acceler real world uptak suggest
increas onpattro commerci reach expect slightli detail
discuss earn call note true launch momentum
ramp becom transpar eap patient roll
like next quarter per previou indic base benchmark previou
compar launch alnylam estim onpattro like follow steadi consist
growth curv next quarter
manag also suggest opex guidanc provid call
though revenu guidanc provid anoth coupl quarter least
model assum onpattro revenu us
note differ phrase us versu eu label eu label includ
cardiac benefit result data section us label
disappoint us label continu believ polyneuropathi manifest
major hattr popul present mix phenotyp
neuropathi cardiomyopathi alnylam continu guid hattr patient
alreadi diagnos present polyneuropathi us like
total includ undiagnos anoth europ total like around
diseas awar initi continu gain traction alnylam-
act no-charg genotyp program steadili grow program
test sampl identifi bear posit ttr mutat
manag also expect kol agre diagnost rate like
acceler given gene sequenc advanc avail scintigraphi
practic increas awar
think ultim impact narrow label onpattro opportun
determin willing cardiologist broadli interpret exact label
specif fap document potenti neuropath manifest hattr
patient discreet physician number provid recent pre-
announc prescrib physician mix support good commerci
reach alnylam note start form far submit mix specialist
includ neurologist cardiologist hematologist
specialti like reflect mix fap mix phenotyp patient
distribut pure fap vs mix phenotyp patient releas yet
start form receiv alnylam document precis symptomatolog
specifi document polyneuropathi howev think earli physician mix
metric good indic willing treat mix phenotyp patient
interest potenti tailwind futur onpattro market potenti
pivot givosiran data aip track recal alnylam develop
givosiran treatment acut intermitt porphyria aip compound
produc extrem promis biomark ala pbg reduct
clinic benefit mean reduct annual attack rate annual hemin
use phase ole trial current phase develop
treatment produc highli signific decreas urinari ala patient random
givosiran treatment mg/kg qm vs placebo safeti result
reflect data porphyria patient treat least three month
suggest rel benign profil sae treatment arm vs
placebo one discontinu givosiran arm relat increas
liver transaminas activ protocol-defin discontinu rule
accompani increas bilirubin trigger hy law
resolv without use steroid treatment whatsoev
full top-lin attack rate data expect earli think like march given
expedit timelin base encourag feedback fda alnylam
initi roll nda clinic portion anticip complet mid-
impli potenti late approv us eu believ
investor view aip limit opportun though broad label includ
patient sporad attack think like could constitut signific
cowen street consensu estim
consensu y/i
consensu y/i
upsid possibl onpro share
biosimilar launch
investor watch impact
consensu y/i
 sale declin due competit
consensu y/i
consensu q/q
consensu q/q
unreli due chang
part part
sale data suggest revenu line
consensu
settl teva
briefli launch sensipar gener
though good
proxi kyproli
consensu q/q
consensu y/i
major sale ex-u sale
like in-lin consensu
cowen compani consensu
consensu y/i
consensu q/q
scrip q/q
consensu q/q
though deterior price could
result shortfal
earli aimovig scrip trend
solid suggest revenu
less line consensu
biosimilar
estim consensu seem
expect cost save share
repurchas bring ep least
line consensu
report date tuesday januari confer call et
earn summari prescript trend number franchis
neupogen/neulasta epogen nplate track somewhat consensu
sever aranesp prolia xgeva track behind balanc think consensu
total revenu estim achiev think financi flexibl
particular abil control cost repurchas share also result non-
ep least line
confer call topic topic discuss amgen call may includ
aimovig launch dynam light recent launch competitor anti-cgrp
ajovi emgal biosimilar competit neulasta franchis fulphila
udenyca repatha price demand trend wake new discount
arrang competitor introduct new discount ndc
repatha on-going enbrel patent litig sandoz potenti abil
fend gener competit sensipar via patent settlement parsabiv launch
pipelin particularli reinvigor effort oncolog
enbrel enbrel price dynam turn much less favor
guid similar low singl digit y/i price declin sale
less in-lin expect y/i reflect continu trend
modest declin volum net price
accord iqvia enbrel scrip q/q reflect slow
deterior drug posit rheum derm market long-term
demand price trend erod moder think enbrel sale like
in-lin consensu estim y/i
beyond increasingli evid franchis continu see eros
estim enbrel sale declin compound-annual-growth-rate
price pressur pick steam competitor gain share
iqvia health cowen compani
su sandoz novarti patent infring argument heard
new jersey district court trial began septemb
close argument novemb anticip verdict recal
sandoz biosimilar etanercept erelzi garner fda approv august
launch stymi due much back forth two compani
procedur bpcia patent danc file suit sandoz infring
composit matter patent manufactur patent three use
patent investor appear contempl risk
neg decis could lead potenti nearer-term launch
sandoz erelzi fortun legal consult believ key
composit matter patent might chanc hold court
sandoz main critic doubl patent also express high confid
ip posit continu make invest enbrel brand
patent stand enbrel would enjoy anoth year exclus
patent expir
neupogen/neulasta novartis/sandoz launch zarxio g-csf first
biosimilar approv fda zarxio launch discount
join teva granix g-csf competitor market
short-act g-csf zarxio follow granix footstep slowli
novemb granix market share held steadi sale
y/i octob novemb show sign stabil fact
octob launch filgrastim biosimilar nivestym steepest discount
yet neupogen wac suggest neupogen declin could acceler
iqvia cowen compani
neulasta long-act g-csf drug far bigger drug though
fulphila second bsufa date june approv somewhat surpris
came without adcom panel fda previous turn sever
biosimilar neulasta applic fulphila price discount wac compar
neulasta though believ neulasta fulphila similar
differ novemb fulphila captur pegfilgrastim
market though believ launch hamper suppli issu
coheruss biosimilar udenyca receiv fda june fda
accept resubmiss bla grant approv novemb
udenyca launch januari discount wac neulastaon
pariti biosimilar fulphila sandoz biosimilar applic receiv
juli expect resubmit applic consensu estim
call y/i declin neulasta sale appear reason stage
meanwhil defens strategi hing larg on-bodi neulasta auto-
injector devic onpro launch earli on-bodi devic
steadili gain market share exit share neulasta market
note mani hospit system made consciou decis switch onpro
adjust nurs schedul protocol procedur result amgen
expect onpro market share somewhat sticki wake neulasta
biosimilar segment market like difficult mylan/biocon
accord iqvia neulasta/neupogen sale y/i first two
month consensu call y/i declin sale henc expect
neulasta/neupogen sale could significantli consensu
neulasta trend key focu investor model project
neulasta revenu meanwhil cowen
specialti pharma team project coheru cover ken cacciator achiev
udenyca revenu grow
achiev fulphila revenu
aranesp aranesp sale stabl much larg part due
increas uptak dialysi center took advantag aranesp greater
conveni lower price forestal competit mircera recent
competit appear catch aranesp iqvia sale data good
proxi report sale sale y/i octob novemb
ex-u aranesp sale repres total also declin
henc expect sale may come consensu y/i
epogen epogen year monopoli end roch launch mircera
pegyl erythropoietin roch subsequ sold right drug galenica
freseniu becom major custom convert nearli
dialysi patient mircera believ epogen sale
stabil iqvia confirm januari extend epogen suppli
agreement primari custom deal provid
price discount return long-term certainti demand could surpris bit
upsid iqvia suggest y/i decreas sale versu consensu
expect y/i declin
iqvia cowen compani
xgeva iqvia quit accur track sale sale trend appear
season soft xgeva see season stock base iqvia
report sale octob novemb sale q/q bear
mind decemb month sale track ex-
 sale rel steadi year
impli world-wide sale math suggest
consensu estim achiev may hold upsid
prolia demand prolia also tend season sale typic weak
reimburs author summer season strong
consist trend scrip q/q declin q/q
howev consensu call even greater increas ex-u sale
also season world-wide consensu might bit stretch
prolia xgeva monthli sale accord iqvia
iqvia cowen compani
repatha repatha approv treatment hypercholesterolemia august
drug launch disappoint thu far physician interest prescrib
thwart reimburs pushback
manag report sign eas payor commun sign
improv sale trajectori modest investor remain skeptic
potenti inflect repatha scrip repatha sale
follow multipl downward revis sell-side estim comparison start
consensu project repatha sale reach sale
repatha y/i y/i
y/i respect despit sale growth y/i
sale actual declin q/q price concess brought report revenu well
growth unit volum q/q y/i formerli negoti
payor simplifi util manag criteria exchang better rebat
contract gone effect juli net price declin
q/q octob announc launch new ndc repatha
list price reduc out-of-pocket expens medicar part patient
optimist unit volum growth acceler afford improv
patient access expand
iqvia report q/q increas scrip q/q
hand allud continu eros net price less
insight averag rebat expect net price could headwind
therefor anticip result like in-lin somewhat street
expect call q/q sale increas
octob appel court overturn injunct regn/sni
praluent remand case back district court anoth patent trial
januari suprem court deni appeal reinstat injunct
therefor new district court case proceed nonetheless
repatha market share grow market split praluent
remain seen whether regn/sni abl revers trend
heel posit though mostli undifferenti data praluent outcom studi
odyssey well price concess
iqvia cowen compani
aimovig fda approv aimovig may prevent migrain adult
notabl inclus episod chronic migrain approv support
posit data sever phase ii phase clinic trial episod
chronic migrain aimovig price per year medicar part
specialti threshold price believ patient access
drug minim util manag criteria think price make sens
like reflect hesit part price aggress pushback
payor held back repatha commerci launch launch aimovig still earli
day prescript still repres free drug engag success
payor estim approv rate aimovig reimburs util
criteria expect requir patient fail gener therapi physician
iqvia cowen compani
competitor teva lilli anti-cgrp mab migrain teva
ajovi fremanezumab lilli emgal galcanezumab approv
fda septemb prevent treatment migrain adultsth
indic aimovigand price in-lin aimovig ajovi deliv via pre-fil
syring view disadvantag compar aimovig well lilli emgal
deliv via autoinjector monthli administr teva
product test quarterli basi mean patient could
inject ajovi three time everi three month patient might find
appeal aimovig nearli five month head start howev well-receiv
autoinjector place current competit advantag aimovig end fourth
quarter prescript share ajovi share emgal
iqvia data suggest q/q new prescript total
prescript written aimovig aimovig price wac
assum scrip correspond one month therapi
gross net adjust prescript trend would impli end user
demand nonetheless suggest aggress sampl
aimovig expect sizeabl subset prescript
fill free drug consensu impli patient
convert free drug insur coverag think reason
moreov consensu project q/q growth aimovig sale less line
growth total prescript q/q suggest consensu
achiev
kyproli concern rare cv event competit product includ takeda
velcad ninlaro limit kyproliss growth potenti nonetheless
consult continu expect kyproli gain much share
myeloma market base upon superior head-to-head os data vs velcad iqvia
accur track kyproli sale past report increas q/q
sale first two month appear kyproli track less
line consensu
europ kyproli gain approv novemb base upon trial
ec approv label expans endeavor juli ex-u sale
benefit clinic trial purchas otherwis steadi
q/q sale
sensipar/parsabiv januari sensipar move part
reimburs part system alongsid parsabiv sensipar
parsabiv transit esrd bundl result chang iqvia-
report prescript longer much mean
provid total revenu guidanc note high
end guidanc assum sensipar gener launch end
theori gener could launch earli march howev
sign settlement agreement gener compani approv anda teva
gain fda approv gener sensipar late decemb began briefli sell
market settl delay sale anoth
gener compani pend anda optimist near
sensipar remain protect formul patent would expect
sensipar gener launch per negoti settlement prolong
exclus period could benefici amgen effort convert patient
sensipar parsibiv
parsabiv launch januari strong start sale
drug superior toler may allow long-term success
sensipar/parsabiv estim q/q y/i consensu
q/q y/i appear achiev base recent trend
though perhap risk estim teva abl
put lot gener sensipar channel brief period market
vectibix vectibix market share rel erbitux crept upward
past year low around today drug perform even
better ex-u account signific fraction sale expect sale
in-lin consensu
nplate nplate fairli matur franchis benefit price increas
iqvia data indic y/i sale growth octob novemb trend
somewhat consensu project growth
guidanc model project total revenu y/i
non-gaap ep y/i consensu call total revenu
y/i non-gaap ep y/i consensu revenu estim
appear conserv maintain much financi flexibl particular
abil control cost repurchas share therefor would expect top-
bottom- line guidanc least bracket consensu
thesi view better breed pharma compani
centric revenu base biolog franchis rapid dividend growth believ
compani run exceed expect expand margin near end
order multipl expand meaning think newer franchis
must consist outpac investor expect drive meaning top-lin growth
unfortun recent perform made abil clear
undertaken substanti effort improv access repatha
come expens much lower price hope combin
guidelin chang reinvigor franchis re-acceler
scrip aimovig earli prescript trend promis
potenti captur substanti share larg lucr migrain market though
impact compet launch must watch unfortun without
perform newer franchis think moder stock perform
would possibl continu financi engin share buyback cost control tax
save posit beat nearer-term ep expect howev legaci
product drive project product revenu
face new competit and/or price pressur question whether
declin quickli multipl expans would like investor gain
confid abil newer product off-set declin increas
overal product sale absent stock like track ep project growth
period
look potenti launch addit gener sensipar new gener
sensipar settlement possibl district court decis enbrel patent infring suit
sandoz launch even japan even fda adcom possibl updat
pipelin program includ variou bite inhibitor
cowen compani consensu thomson reuter
invest thesi see galafold migalastat activ differenti
monotherapi fabri meaning clinic benefit patient amen
mutat potenti beyond ert galafold approv major
market eu japan australia canada israel switzerland south korea us
price reimburs secur countri nda pend taiwan
see high likelihood approv model peak sale eu
us
also see major valu creation opportun phase readi abt-
co-formul pomp main pipelin program first
candid come fold proprietari chart platform chart technolog
potenti stabil therapeut enzym allow enhanc tissu uptak improv
lysosom activ substrat reduct greater reduct immunogen
reflect extrem encourag result gener pomp far
phase data suggest candid could becom best class ert pomp
better efficaci safeti myozyme/lumizym
recent corpor updat amicu pre-announc galafold sale
versu guidanc estim manag
previous note expect final number come mid-to-high end
rang expect provid opex guidanc increment increas sg
driven potenti submiss approv latam driven new
us launch great start believ us repres
opportun optimist launch given earli convers
us clinic trial patient well quick approv insur
plan suggest propos galafold reimburs strategi
reson well privat public payer recent patient
referr form prf start form count patient significantli
doubl compani initi project patient end year
patient treat far ert-switch clinic
trial patient expect strong momentum set solid base
revenu amicu guid impli y/i
growth think earli number speak volum high demand
drug unsurpris given galafold market europ
year excel real-world experi also
encourag prescrib base exceed physician total
target md treat vast major us fabri patient per
manag potenti sourc growth acceler us
includ us regul allow compani market directli patient vs
eu higher number diagnos untreat fabri patient eu
newborn screen like acceler diagnost rate
newborn three famili member typic diagnos
amen mutat
eu launch still go strong galafold gain approx
penetr within amen previously-tr patient year post-
launch market share close earli launch countri
germani uk amicu still see plenti space grow geographi
though given bucket diagnosed-but-untr patient
target next adher complianc rate remain extrem high
like reflect conveni drug amicu also note
encourag chang pattern prescript physician start
provid patient prescript countri center
start submit larger bulk order drove lumpi
recent japanes galafold approv like meaning contribut sale
per manag recent indic japanes launch
smooth start oper effici amicu continu
expect territori contribut significantli galafold opportun given
high diagnost treatment rate fold market research estim
approx patient region treat
high level interest commun manag indic recent
launch symposium attend healthcar provid
possibl home infus japan make ert treatment
burdensom territori low reimburs hurdl
manag continu anticip japanes launch mechanics/dynam
similar seen germani think peak market penetr
reason see ad approx sale
total peak sale
recal recent acquisit provid amicu platform aav gene
therapi program ip spun nationwid children hospit ohio state
univers follow-up collabor agreement wilson laboratori
univers pennsylvania gene therapi program gtp expand pipelin
gene therapi pompe- fabry- defici diseas well one
addit undisclos rare metabol disord program target space high
unmet need amicu estim could potenti target patient
total base current strategi amicu manag remain confid
abil advanc multipl program parallel recent corpor
updat provid granular upcom catalyst
recal nch construct current test single-
arm phase clinic investig studi led dr jerri mendel twelv
patient enrol treat far singl intrathec
administr vg amicu believ
like optim dose proven safe far time
acquisit encourag see efficaci observ patient
match sibl pair mutat follow
month two-year follow-up hamburg score motor languag subscal
data show symptom diseas progress younger patient
treat year age limit progress follow
potenti diseas stabil older sibl treat year age
follow-up data patient well year data least half
patient includ least one sibl pair think
present
batten diseas phase studi initi amicu indic first
patient dose studi good safeti far trial
enrol addit seven patient administ one two gt
dose time data tbd manag note given slow
progress diseas like wait report follow-up data
cowen compani consensu thomson reuter
aptinyx promis valu proposit base nmda pipelin discoveri
platform see focu nmda chemistri highli differenti
compani attempt modul sensit yet power receptor class
close link synapt plastic see solid rational preclin poc
safeti lead program phase dpn potenti blockbust sale interim
result on-going exploratori phase trial fibromyalgia
encourag show compel imag biomark pain relief associ
preliminari clinic benefit albeit small number patient aptx plan start
phase fibromyalgia trial first poc data chronic pain bode
well on-going phase trial dpn data due januari februari also
view earlier stage candid promis ptsd pdd respect
see addit valu creation allergan research collabor
first half expect success
aptx current evalu efficaci safeti lead nmda modul phase nyx-
treatment pain dpn diabet peripher neuropathi double-
blind placebo control studi subject subject dose daili
four week multipl dose rang mg follow-up
period one week pain assess use patient report scale pain score
zero ten record daili provid hand-held devic studi assess
daili pain score baselin seven day prior treatment throughout studi
durat prior random protocol remov subject whose daili pain score
exhibit signific day-to-day variat associ higher rate
placebo respons success could provid rapid long-last pain
symptom resolut fewer side effect low potenti abus liabil
treatment may also enhanc patient complianc due simpl dose regimen aptx
expect releas top-lin phase data first half expect success
base posit preced preview expect trial data
aptx conduct exploratori phase trial fibromyalgia studi
single-blind placebo-control studi target enrol subject
goal studi determin whether daili dose mg mg
affect certain biomark central pain process use function magnet
reson imag fmri subject serv control receiv
placebo six week studi interim analysi first
patient complet studi show met primari endpoint
reduct combin glutam glutamin level glx assess fmri
certain key brain area view interim result encourag potenti
clinic meaning anticip continu demonstr clean
safeti profil could potenti key differenti competit fibromyalgia
product complet data exploratori trial read aptx plan
initi phase fibromyalgia trial aptx highlight
phase trial would patient tradit pbo vs treatment trial multipl
patient-report pain scale measur primari endpoint
cowen compani consensu thomson
braftovi/mektovi sale estim
consensu estim
total revenu estim
line consensu estim
ep estim compar
consensu estim
earn summari expect calendar earn center
second full quarter mektovi/braftovi sale us braf-mut melanoma
manag explicit consist deliber commentari regard
initi trajectori launch like slow given anticip market
dynam go two establish competitor novarti
entrench market share leader consid tone commentari execut
initi essenti extent physician coverag formulari posit
insur coverag provid insight first commerci launch compani
remain confid arri manag hit mark line logic
meter previou commentari recal initi sale surpass
expect includ arri anecdot observ patient activ
switch target regimen even without diseas progress
view strong vote confid physician importantli believ
sign prescript data decemb quarter indic interim
flatten reflect fact switch patient
inventori work true underli demand come
new patient start remain solid track expect
beyond launch progress ou advanc pipelin remain central
thesi look commentari braf-mut program well
hint regard io combin program enabl appropri diffus
investor attent simpli launch dynam consid best-in-class
regimen braf-mut melanoma compani intermedi long-term
braftovi/mektovi follow commerci launch juli look
commentari regard on-going initi us launch effort discuss
manag believ execut rel smooth surprisingli strong
first quarter sale vs estim like reflect academ
physician commonli treat metastat melanoma payer familiar
braftovi/mektovi best-in-class profil though certainli posit sign near-
term expect switch contribut total script less meaning
backlog patient older regimen switch off-set
instead patient initi braftovi/mektovi first choic
prescrib switch patient mid-regimen
combin becam avail thu believ futur quarter
expect outpac estim wide margin point manag prudent
keen highlight well braftovi/mektovi sale take place non-retail
channel hospit visibl script trend throughout quarter
third-parti data sourc limit like go forward make launch
trajectori challeng project
pipelin updat arri lead pipelin program braf-mut led
beacon pivot studi continu make progress follow updat safeti
lead-in alreadi show strong initi result june gi januari
interim beacon readout orr expect may
potenti support acceler approv addit compani studi
line set anchor commenc primari complet
clinicaltri gov estim given efficaci toler profil
evid thu far patient line set come
welcom albeit somewhat anticip updat plan underway explor use
line set
year-end look arri present initi data sever on-going io
combin effort led partnership steve scala combin
binimetinib nivolumab /- ipilimumab mss expect remain low ahead
prospect data part owe neg read competitor trial
recent kol panel cowen confer suggest
investor remain skeptic specialist see potenti mechanist rational
look commentari progress multipl program includ next
first line studi partner merck steve scala mss non-
indic pfizer steve scala expect gener initi clinic data
invest thesi see arri well posit garner valu sharehold
compani perenni product engin feed compani clinic
pipelin commerci effort vs prior histori outlicens promis agent
despit potenti challeng entrench competitor initi mek/braf
launch exceed expect continu ramp could slow rel
street typic impati expect said believ oncolog superior
data overal profil prevail continu expect commerci success
highli competit share posit come year consequ
expect braf mss program drive upsid data
updat come month
braf melanoma launch us braftovi/mektovi updat progress
execut near-term outlook shape expect follow
updat pipelin progress particular braf beacon
anchor line mss program bm
updat cadenc addit pipelin busi develop
option year ahead
cowen compani consensu thomson reuter
audent bold gene therapi compani focus develop treatment
monogen orphan diseas primarili affect young patient compani lead
asset treatment xlmtm addit program crigler-
najjar syndrom pomp diseas bold present encourag addit
phase interim data week follow-up xlmtm
aspiro trial four week data one patient dose higher dose
show remark efficaci improv clean safeti view updat
grow alreadi strong bodi data support potenti confer
transform clinic benefit xlmtm also view bold phase crigler-najjar
program preclin pomp program promis
recal phase aspiro studi x-link myotubular
myopathi xlmtm updat program jan may oct
demonstr consist ever improv clinic benefit therapi
data updat follow-up data low-dos cohort show durabl
improv chop-intend improv ventilator-tim mip congruou
express encourag addit trial patient reduc
elimin ventil requir secondari consist durabl fact
increas benefit pulmonari function data suggest durabl
benefit kol spoke strongli believ chop-intend respiratori
function continu improv time believ favor posit
xlmtm orphan drug rare pediatr diseas rmat fast-track design
limit competit bold confirm met fda ema
product interact potenti regulatori path forward includ
discuss potenti pivot data set statist bold provid addit
color updat receipt final fda meet minut
crigler-najjar cn valen program updat expect
audent develop treatment crigler-najjar syndrom cn
recal first patient dose februari low dose vg/kg
first data updat releas may show safeti signal includ
lft elev t-cell mediat respons anti-ugt antibodi detect bilirubin
level drop baselin mg/dl day start
rebound day back baselin day data mirror observ
anim model low dose audent plan escal dose treat
next patient plan mid-dos vg/kg compani
believ could show sustain express base preclin anim data
howev enrol stall due high patient screen failur due
observ adolesc cn patient manifest liver damag relat diseas
bold provid program updat remain cautious optimist
data believ preced preclin model data support clinic success
pomp issu address new construct ind slate
audent program pomp diseas potenti address
shortcom pomp ert like low gaa uptak target tissu
immunogen recal ind submiss program origin
plan due dose escal safeti signal issu nhp preclin
test push earn confer call bold announc
resolv issu fine-tun vector construct share
detail due competit pressur pomp gene therapi program
develop suspect compani move forward altern promot
may muscl specif bold plan file ind on-going mous
studi well plan nhp studi complet compani
plan initi phase studi late-onset adult infantil pomp patient
aptx develop aav base therapi neuromuscular diseas
broad market potenti aptx announc plan disclos indic
program detail
cowen vs street consensu estim
ww sale may fall consensu prescript
trend track estim
tecfidera scrip quarterli sale may fall
sale like come line consensu
patient add could drive ww sale
like base sale trend
spinraza revenu could aid in-lin ms
perform quarter consensu appear
cowen compani bloomberg consensu
like turn toward spinraza competit
n-t financi monitor perform
like determin
investor percept aducanumab chanc
report date januari confer call estimate
earn summari expect post revenu earn least line
consensu despit middl perform sever ms product tecfidera
avonex/plegridi revenu aid solid ocrevu sale continu growth
spinraza outsid upsid product revenu appear possibl wholesal
built inventori biib ms product front januari price increas
biib multipl scleorosi busi stabl suspect investor
increasingli debat spinraza abil weather competit launch year
progress discuss like turn aducanumab chanc success
alzheim front data releas els think
perform determin investor percept
confer call topic expect biogen call focu potenti pivot
plan expect aducanumab interim look launch metric
spinraza focu ex-u market updat pipelin
includ sma gene therapi progress earli stage neurolog develop
impact ocrevu ms market includ earli sign use eu
plan bioepi post-exercis option includ potenti monet
tecfidera tecfidera shortcom associ pml observ
breakthrough diseas difficulti complianc gi toler problem
well document led modest share deterior howev
trend halt tecfidera share total ms prescript increas
figur exclud infus drug
ocrevu tysabri ww tecfidera sale rebound season weak
remain essenti flat accord iqvia tecfidera trx
howev drug overal market share remain consist
iqvia trend somewhat mislead short term appear biogen
effort spread best practic around gi advers event manag led
stabil prescript trend
earn call manag indic new start tecfidera
highest sinc launch ocrevu nrx decreas
howev nrx market share remain consist
term overal market iqvia report total ms prescript volum increas
q/q follow decreas q/q note short term
trend ms market mislead iqvia retrospect acknowledg
data error impact ms market multipl occas past month
report tecfidera sale q/q y/i
factor decreas prescript would result sale
consensu
launch tecfidera europ drug perform
reason well term patient drug lower ex-u price issu ex-
 volum growth also often obscur combin fx headwind
parallel trade dynam inventori fluctuat report ex-u
tecfidera sale q/q y/i tecfidera japanes launch began
late decemb tecfidera maintain market share
japan absenc major new territori expect ex-u tecfidera demand
flat see consensu achiev
would lead world-wide tecfidera sale
consensu nonetheless possibl wholesal
inventori stock front price increas taken januari
avonex plegridi avonex/plegridi interferon franchis cede share
oral ms drug sever year report interferon sale
q/q y/i consist q/q y/i avonex
q/q y/i plegridi total avonex trx
decreas q/q accord iqvia would impli demand
would suggest sale line consensu
ex-u avonex sale also hurt competit oral biogen
report ex-u avonex sale q/q y/i biogen hedg
strategi shield approxim ex-u avonex sale month advanc
therefor anticip littl fx impact q/q basi assum abnorm order
expect quarterli ex-u avonex sale rang set
street model would lead world-wide avonex sale
line consensu model
plegridi expect cannib avonex also grow biib market share
overal ifn market drug launch disappoint sale trajectori
essenti flat consult note higher rate inject site reaction plegridi
believ patient avonex grown comfort year im
inject see littl reason switch iqvia report plegridi trx number decreas
q/q previou quarter report ex-u
plegridi sale expect continu report ex-
 plegridi sale would lead ww pledgridi sale line
consensu model
price increas taken avonex plegridi begin januari
possibl wholesal stock inventori front could drive
report revenu avonex pledgridi consensu
 market ms therapi weekli prescript trend
iqvia cowen compani
tysabri tysabri sale essenti flat sever year price
increas offset volum declin howev launch ocrevu drove
increas tysabri discontinu particularli common jcv tysabri
patient past four quarter report
report tysabri sale q/q y/i iqvia
indic tysabri sale declin y/i basi decreas q/q basi
first two month quarter therefor prescript trend impli
 tysabri end user demand
ex-u sale q/q ocrevu receiv full eu approv
januari howev still take time broad reimburs therefor
anticip ocrevu still minim grow impact tysabri sale
anticip report essenti flat patient demand lead
ex-u sale
therefor analysi suggest ww tysabri sale
consensu
addit price tysabri increas begin januari
wholesal stock front price increas would provid tailwind
initi phase iiib studi examin extend interv dose regimen
tysabri associ efficaci potenti reduct pml
antibodi revenu demand antibodi continu grow year
rituxan launch record q/q y/i
revenu rituxan/gazyva joint ventur non-ocrevu royalti iqvia sale
rituxan/gazyva first two month q/q basi
y/i therefor anticip rituxan/gazyva jv revenu non-ocrevu royalti
iqvia cowen compani
iqvia cowen compani
entitl royalti ocrevu net sale
disclos royalti rate trigger ocrevu annual sale exceed
given signific royalti estim entitl nearli
ocrevu econom valu roch report strong ocrevu sale
first year market furthermor roch report ocrevu
patient ppm market ocrevu first drug label ppm
therefor would appear ocrevuss avail grow ms market
provid ppm patient approv therapi
roch report ocrevu sale chf iqvia report sale
first two month q/q would impli chf sale
therefor royalti rate anticip record
royalti ocrevu sale ocrevu approv ema januari
howev reimburs like take time eu countri receiv
royalti ex-u ocrevu sale roch report eu ocrevu
sale chf lead royalti conserv
estim contribut togeth expect recogn
approxim world-wide ocrevu royalti
total anticip could record collabor revenu
would well consensu
trend fda approv spinraza nusinersen form spinal muscular
atrophi sma decemb octob confer
physician indic adopt spinraza much enthusiasm especi
type patient major hurdl reimburs logist barrier
first fda drug approv sma requir intrathec deliveri though
survey physician would like prescrib spinraza type sma patient
reimburs ambulatori type iii/iv patient challeng
establish spinraza wac price inject
year year thereaft spinraza launch brisk
ww patient commerci therapi end notabl new
patient start continu slow howev increas
adult therapi compar case prior quarter
ex-u sale continu acceler drive increas q/q ww sale total
anticip report ww spinraza sale beat consensu
report spinraza sale q/q
patient therapi new patient start decreas
averag number dose per patient remain
estim infant pediatr patient adult year
older therapi
assum patient start evenli distribut throughout quarter spinraza
induct mainten dose regimen lead record dose revenu
per patient start first financi report quarter dose revenu
second report quarter dose revenu third report quarter
dose revenu subsequ quarter therefor among patient
start would anticip record dose revenu
start dose revenu start dose revenu
dose revenu dose revenu
dose revenu dose revenu total previous initi
patient would expect gener dose revenu
assum number new patient start drop across new
exist spinraza patient anticip administ dose
spinraza gross-to-net adjust would repres
sale
ex-u spinraza sale spinraza approv eu june gener
ex-u sale grow strongli outsid
 spinraza reimburs countri achiev regulatori approv
addit five countri applic file addit two countri
ex-u commerci patient volum sale grew
respect importantli patient eap end
q/q indic sale growth sustain furthermor ex-u
commerci patient split approxim type
result much room growth type patient within exist territori
end ex-u commerci patient assum ex-
 commerci patient mainten phase patient
requir mainten dose would repres dose averag
price less estim net price would gener
revenu mainten dose continu commerci spinraza
averag number new commerci patient increas patient
past three quarter given increas reimburs environ think
possibl patient come drug howev conserv
estim would new patient quarter
expand access program appear use larg program grant
access spinraza load dose month lead formal reimburs
within countri patient eap program assum
cover formal reimburs agreement mainten
dose phase treatment patient would util dose
spinraza averag price would translat revenu
eap patient transit onto commerci therapi
would leav addit patient start commerci spinraza
sinc patient pass eap like requir full
cours load dose assum averag patient complet load dose
patient would gener dose spinraza
averag price would repres revenu would lead
total ex-u spinraza sale lead world-wide sale
consensu
investor begun debat impact competit spinraza panelist
survey specialist octob confer optimist
novartiss sma gene therapi clinic standpoint believ
futur soc could combin therapi spinraza acknowledg
reimburs hurdl consid price tag two drug togeth
think work panelist note patient amen
spinraza treatment due spinal deform would earli adopt
due iv rout administr recent encourag ptc/roch risdiplam
phase data specialist optimist risdiplam also succeed pivot
trial consult expect risdiplam could present competit threat
spinraza due oral dose consult think spinraza inject may
still first choic infant pediatr patient would struggl take oral
therapi suspect risdiplam prefer older patient therefor
suspect risdiplam data close monitor investor
eu biosimilar benepali biosimilar version pfizer/amgen enbrel develop
samsung bioepi jv samsung biolog benepali approv
ema europ launch samsung bioepi also receiv ema
approv fliximab biosimilar remicad juli ema approv inraldi
biosimilar humira though launch imraldi octob
follow april patent settlement hold commerci right
benepali fliximab inraldi europ book product-rel sale
expens
report q/q y/i biosimilar revenu
benepali market nearli year fliximab two half suspect
neither wit major acceler though imraldi launch
octob anticip take sever month european govern request
begin execut tender offer therefor minim sale
therefor anticip biogen eu biosimilar revenu less flat q/q
hope acceler growth imraldi begin
penetr eu market
vumer file fda partner submit nda
vumer hope pathway approv submiss
includ data singl arm two-year safeti studi rrm patient data cut june
pharmacokinet bridg analysi tecfidera clinic studi
shown equival efficaci tecfidera howev importantli much improv
toler discontinu rate due gi within first month
treatment seriou gi
headto-head comparison studi vs tecfidera gi toler yield data mid-
data continu suggest improv gi profil vumer could help
biib franchis recaptur share importantli vumer ip protect thought
approxim year longer tecfidera therefor could provid
valuabl extens ms franchis well
thesi think share attract valu investor
reward steadi perform ms franchis continu spinraza
growth grow anticip aducanumab phase data alzheim earli
howev long-term outlook mix ms franchis spinraza
like face addit threat pipelin rel earli outsid
mix excit around therefor aducanumab earli data releas
shape major binari event share
look potenti plan develop updat
plan biosimilar jv follow exercis option potenti updat
respons clinic hold initi sma gene therapi candid potenti
updat regard vumer regulatori process expect launch addit
busi develop deal augment pipelin
cowen vs street consensu estim
recently-reaffirm guidanc impli
recently-cut guidanc impli
recently-reaffirm guidanc impli
due chang revenu recognit methodolog
quarterli sale may difficult predict estim
recently-reaffirm guidanc impli
recently-reaffirm guidanc impli
recently-reaffirm guidanc impli
revenu
ep
non-gaap ep
estim assum palynziq begin cannib kuvan
recently-issu guidanc call
estim assum y/i growth consensu
project bmrn guidanc mid-teen
investor keen see continu ramp toward
cowen compani consensu bloomberg
report date mid late februari
earn summari last week biomarin reiter element guidanc
adjust guidanc rang rel tight think littl
potenti major financi surpris fact mani way post-quart guidanc
akin pre-announce time provid guidanc
palynziq though yet issu guidanc line trajectori
franchis well bmrn expens line pretti well defin
big surpris expect would seem unlik
import bmrn pipelin ph data vosoritid achondroplasia
anticip ye decis whether pursu acceler file strategi
val rox hemophila commun think acceler file
like bmrn solid base busi break profit
pipelin appear capabl drive mid-teen revenu growth well next decad
continu consid core mid-cap biotech hold
vimizim project vimizim sale q/q y/i vimizim
consensu biomarin recent reiter guidanc impli
sale alway visibl vimizim quarterli sale
low report revenu heavili influenc larg lumpi order
ex-u countri exampl vimizim benefit larg brazilian order
one receiv consensu estim may
aggress nonetheless patient therapi grow approx per year
vimizim would appear much long term growth left
kuvan kuvan estim q/q y/i consensu
last week kuvan net product revenu guidanc reduc
impli kuvan revenu
bracket estim consensu impli less line revenu
note kuvan continu perform driven increas uptak
north america us kuvan patient growth y/i continu
develop ex-u market
biomarin reach settlement pharma allow kuvan gener enter
 market follow settlement dr reddi kuvan
gener expect biomarin abl transfer
larg percentag kuvan patient palynziq earli launch
palynziq launch guidanc impli rapid uptak palynziq pegvalias
grant full approv may product becam avail first week juli
last week biomarin disclos decemb patient
reimburs palynziq includ clinic studi patient formerli nave
patient addit site least one patient therapi
end total clinic prescrib palynziq least one
patient patient either naiv clinic studi
receiv reimburs commerci treatment earn call manag
indic naiv patient come previous kuvan
given modest revenu contribut palynziq-na patient earli
month therapi time need convert clinic trial particip
commerci therapi palynziq revenu rel modest last week
reiter palynziq guidanc impli revenu
 estim consensu nonetheless
biomarin issu new palynziq guidanc impli
revenu ramp meaning
review palynziq eu manag anticip regulatori
decis
biomarin estim adult pku patient
tri kuvan catalogu biomarin registri adult patient
current kuvan leav patient tri kuvan without success
anoth activ treat pku clinic anoth activ
treatment biomarin disclos eu turkey anoth adult
patient kuvan patient clinic clinic
consult correct think palynziq captur number patient
kuvan would translat market opportun
consist palynziq estim biomarin analysi
support market opportun
anticip signific portion quarterli call focu biomarin
continu launch progress expect ramp proceed
naglazym sale estim q/q y/i
consensu last week reiter naglazym guidanc
 impli sale naglazym sale
heavili influenc larg order ex-u territori fact benefit
brazilian order estim consensu assum rel larg q/q
declin would seem achiev naglazym continu grow steadili even
though market decad number patient
naglazym grew y/i
aldurazym project biomarin report aldurazym revenu
q/q y/i stem aldurazym end user sale
consensu call biomarin record aldurazym revenu aldurazym
revenu recogn time transfer sanofi/genzym rather time
product sold genzym custom therefor quarterli revenu lump
difficult predict prior guidanc call aldurazym revenu approx
would suggest aldurazym revenu approx howev
aldurazym guidanc reiter last week therefor estim
brineura late april brineura receiv fda approv treatment
diseas patient year age older biomarin price brineura wac
per two week suppli impli annual wac though biomarin said
expect discount take account expect complianc averag net price
expect
biomarin launch brineura mid-jun compani indic
launch progress well gradual steadi ramp across new countri
treatment site biomarin note continu expect uptak gradual
wareh patient full reimburs ex-u territori
take time brineura produc revenu impli approx patient
therapi
biomarin recent reiter guidanc would impli
brineura sale estim approxim
patient consensu patient given brineura trajectori
foreign exchang impact total revenu approxim biomarin revenu
come europ impli euro-denomin sale
howev biomarin hedg exposur profit therefor impact
bmrn bottom line rel modest move euro usd exchang rate
minim
invest thesi biomarin leader develop therapi
orphan diseas discount cash flow analys suggest biomarin base busi
worth vimizim worth addit project
brineura revenu potenti dcf analysi suggest could
worth biomarin dcf analysi suggest vosoritid
achondroplasia could worth notabl pipelin program
includ valuat analysi includ val rox gene therapi hemophilia
two pivot phase trial tralesinidas alfa mp earli
stage potenti pivot phase ii project biomarin revenu increas
drive biomarin profit expect biomarin
share outperform market next month solid perform
market product continu launch vimizim brineura palynziq
progress program pivot develop approach regulatori approv
look continu launch metric patient treat commerci
pegvalias chmp opinion palynziq potenti releas data val rox phase i/ii
hemophilia potenti ind submiss friedreich ataxia
cowen vs street consensu estim celg
full year guidanc impli approx revenu
full year guidanc impli approx revenu
full year guidanc impli approx revenu
full year guidanc impli approx revenu
full year guidanc impli total revenu
fy guidanc impli non-gaap ep
guidanc
guidanc
guidanc
guidanc
guidanc
guidanc
cowen compani street consensu provid celgen excl option expens up-front collabor payment sever addit item
earn summari celgen announc earlier month achiev
financi guidanc provid financi guidanc guidanc
year found tabl celgen re-affirmed goal
total revenu non-gaap ep greater dont
anticip stock movement durat celg time list public
compani driven financi howev januari bm scala announc
intent acquir celgen cash stock transact ev celg
sharehold receiv one bm share cash per celg share addit
celg sharehold receiv conting valu right cvr celg share
whose valu depend futur regulatori mileston holder entitl one-
time payment ozanimod liso-cel approv decemb
approv march acquisit expect
close
regulatori pipelin highlight nda fedratinib treatment
myelofibrosi submit target action date anticip
submiss ema anticip celgen remain on-track
resubmit nda ozanimod rm enrol phase
north studi ozanimod uc expect complet regulatori
submiss luspatercept md beta-thalassemia also plan
 eu pivot data transcend studi liso-cel dlbcl
expect regulatori submiss plan pivot studi
cll slate commenc pivot karmma data rrmm
expect
given bmi offer celg expect close perhap import
near-term earn would develop could put deal risk
opinion advers rule celg patent case would suffici
materi expect final decis patent
disput
expect pto decid whether dr reddi ipr challeng
revlimid md use patent heard august dr reddi file three
ipr celg patent use
patent claim use revlimid treat myelodysplast syndrom statut
 pto six month decid whether institut ipr mean
decis institut due februari institut pto
would year determin whether patent stand invalid
notabl three patent claim use revlimid treat md order
launch dr reddi would need invalid demonstr infring
revlimid orang book list patent notabl revlimid polymorph
patent therefor matter result ipr process believ dr reddi would
still need prevail district court case subsequ appeal celgen
celgen expect district court case render verdict late earli
appeal last addit month verdict mid-to-l
look addit mileston possibl data
phase robust trial dlbcl possibl data phase apact studi
abraxan pancreat cancer march pdufa data tecentriq abraxan
cowen vs street consensu estim
bloomberg cowen compani
dynavax indic sale
less
hope heplisav sale
acceler
estim consensu project heplisav sale q/q
in-lin street consensu file januari disclos
heplisav sale less impli upsid
estim consensu
heplisav hepat vaccin fda approv novemb launch
januari receiv acip recommend april
heplisav sale ramp gradual manag encourag
heplisav recept month follow launch superior efficaci fewer
dose caregiv attract profil enthusiast
option patient base earli feedback dynavax remain convinc
heplisav becom standard care hbv vaccin time
logist get heplisav pharmaci committe
onto formulari gate avail uptak earli januari
dynavax announc largest custom receiv committe
approv made purchas implement use heplisav
throughout system earn call custom
 committe made purchas implement
heplisav throughout system number target account
committe approv repres target market
heplisav estim assum share hepat vaccin
market without allow market expans new popul diabet
think estim reason expect heplisav becom market-
lead hbv vaccin time consult find particularli compel
heplisav consist produc higher rate engerix-b consult also
impress heplisav reduc number requir inject offic visit
say difficult get mani patient return offic third shot
month six older vaccin requir think heplisav regimen dose
month much conveni lead better complianc
dynavax guid submiss heplisav eu
sever data set trial tlr agonist combin keytruda
esmo naiv metastat melanoma keytruda produc
orr patient vs orr patient present
keytruda produc orr patient vs orr patient
present time follow-up call manag indic one
pr cohort advanc cr two pr cohort
six-month patient receiv drug median
reach sever respons persist two year
result compar favor efficaci keytruda monotherapi produc
pivot trial ipi-na melanoma studi keytruda produc
orr median month manag continu evalu
partnership opportun advanc phase studi indic
enrol continu keytruda dose cohort phase ii studi
patient experienc metastat melanoma esmo six patient
respond given keytruda includ one complet respons
correspond orr cr rate data demonstr
inject non-inject lesion shrunk median follow-up approxim
day data immatur assess durabl respons manag
complet enrol keytruda dose cohort phase ii
studi patient head neck cancer naiv therapi
receiv one prior round system therapi time esmo
patient cohort evalu respons cohort
orr pr evalu patient stabl diseas
group durat respons month manag anticip initi
phase ii/iii studi keytruda front-lin cancer possibl earli
compani use data dose cohort on-going
studi determin appropri dose take forward data gener thu
far cancer compar well orr seen keytruda monotherapi
dynavax updat data three studi think
minim valu stock today therefor success develop
would major driver sharehold valu
thesi dynavax heplisav hbv vaccin shown
effect conveni current market hbv vaccin number
phase trial launch januari heplisav recent phase
subject trial primari efficaci endpoint seroprotect
rate within subset patient type diabet heplisav-b gener
statist signific superior maxim compar engerix-
 consult expect superior seroprotect requir fewer
inject allow heplisav captur signific share ww market
adult monoval hbv vaccin compani advanc develop candid
class cpg agonist ph ii combin keytruda
melanoma head neck cancer think under-valued base larg
potenti heplisav-b hbv vaccin market
look addit detail around launch heplisav safeti
biomark data phase ib dose escal studi nsclc initi
ph ii studi potenti updat clinic path forward detail potenti
partner potenti submiss heplisav
pre-announce preliminari revenu revenu
pre-announce ni ni
pre-announce adj ni adj ni
street consensu bloomberg sourc cowen compani
emerg biosolut report preliminari revenu beat
estim in-lin previou guidanc follow
adapt pharma paxvax acquisit midpoint reflect revenu growth
compani indic increas due sale
raxibacumab narcan higher revenu off-set lower biothrax
revenu revenu histor driven larg deliveri biothrax
result quarterli financi choppi unpredict compani close two
transact continu diversifi revenu stream bring
product offer manag guidanc revenu
rais reflect remain biothrax deliveri
increment opportun narcan acquir adapt pharma well vaxchora
vivotif acquir paxvax compani guid revenu
y/i fy estim issu prior
achiev compani revenu goal guid revenu
estim like relat lumpi revenu
recognit time year consist histor experi
expect compani earn call focu progress nuthrax
manufactur phase develop updat follow-on contract
negoti detail key driver financi guidanc
pipelin updat addit product licens discuss
steadi biothrax sale compani portfolio expand product
follow paxvax acquisit biothrax still constitut largest portion ebss
revenu despit decreas due revenu recognit time biothrax
revenu remain key profit
driver biothrax higher margin provid biothrax center diseas
control prevent cdc biomed advanc research develop
author barda two contract cdc contract sign decemb
valu call deliveri million dose strateg
nation stockpil sn septemb price per biothrax dose
subject annual price escal remaind
contract addit march manag announc barda award
contract call worth addit biothrax period month
plan deliv approxim nine million dose biothrax sn
thu yearli project biothrax sale fairli straightforward
manag emphas time biothrax deliveri contract
difficult predict henc lumpi evid quarterli basi though
annual shipment predict
nuthrax develop continu first sale expect nuthrax
import growth driver septemb award competit
contract allow develop nuthrax deliv initi dose
vaccin sn follow emerg use author eua pre-approv
contract includ option govern procur dose
nuthrax potenti valu hope deliveri
could begin earli potenti post-market commit valu
henc govern exercis option contract valu
current model us govern exercis option believ
investor expect well may also expect procur continu
beyond horizon estim averag per-dos cost nuthrax base
full exercis option time order nuthrax contract
like lumpi year year downsid risk us govern may
choos exercis procur option may take longer
anticip current develop valid nuthrax releas assay plan
initi phase trial submit applic nuthrax
emerg use author decemb expect review
grant would allow deliveri sn
anticip deliv aggreg dose biothrax nuthrax
make use build capac ebss new biothrax contract use bldg
full capac biothrax dose per year result anticip
manag util addit capac produc biolog manag
maintain small amount biothrax product build work
transit manufactur product sole build biothrax
nuthrax build use program includ expans
compani busi manag hope leverag german approv
build attain contract nato govern april
biothrax grant market author five addit european
countri itali poland franc netherland mutual
recognit procedur base germani europ biothrax
market bacithrax howev previous indic foreign govern
contract difficult achiev target total sale outsid
grow non-biothrax busi manag activ engag
expand biodefens product portfolio acquisit acquir
right militari grade auto injector award depart
state contract manufactur deliv addit trobigard train auto-
injector work european supplier modestli expand output
identifi supplier match demand auto injector requir
fda approv prior use manag anticip initi two human
factor studi near-term plan develop addit auto-injector well
contract medic cbrn defens consortium mcdc juli
announc award mcdc contract fund
develop novel multi-drug auto-injector nerv agent antidot deliveri
octob close acquisit live small pox vaccin
approxim sale potenti start deal emerg
also acquir cdc contract million remain valu set expir
septemb receiv fda approv make canton
facil began deliveri cdc late expect govern demand
somewhat uncertain revenu depend follow-on
contract negoti posit govern establish stockpil
product tend maintain note competitor bavarian nordic
develop smallpox vaccin imvamun produc posit phase data
februari though drug yet fda approv expect approv
barda award pre-approv procur contract imvamun includ
dose older liquid-frozen formul approxim dose
freeze-dri formul approv anticip howev bavarian
nordic target inact vaccin patient sever immunodefici
activ vaccin like otherwis contraind confid
govern want activ vaccin well model
sale per year in-lin histor demand pend addit clariti
addit octob close acquisit raxibacumab
monoclon antibodi treatment prophylaxi inhal anthrax gsk
total consider deal emerg acquir intellectu
properti right raxibacumab remaind exist contract
biomed advanc research develop author barda suppli
raxibacumab strateg nation stockpil sn residu valu
though manag report deliveri made vast major
contract valu remain model raxibacumab sale ramp
project revenu sale compani
biodefens product
octob acquir privat held paxvax all-cash
transact transact fund combin emerg
exist cash credit facil acquisit add two
market vaccin emerg portfolio vivotif oral live typhoid vaccin
vaxchora oral live vaccin cholera product market intern
travel whose destin includ high-risk area compani also gain access
paxvax cgmp product facil us switzerland file paxvax
financi follow acquisit report net product revenu
emerg also acquir adapt pharma privat up-front payment
sales-bas mileston up-front payment includ
cash stock adapt pharma lead product narcan intranas
formul naloxon drug treat opioid overdos anthrax franchis
anticip narcan becom second import driver top line
manag guid revenu deal narcan price
carton qualifi group buyer emerg
servic personnel take mid-point price manag guidanc impli
annual demand narcan dose carton bottom rang
recent joint aadpac/dsarm adcom discuss naloxon co-prescrib opioid
eventu vote narrowli favor co-prescrib
consensu whether naloxon co-prescrib opioid medic best path
forward due project cost program potenti altern
strategi speaker highlight potenti demand naloxon certain
scenario fda present highlight mandatori co-prescrib naloxon
would requir dose annual manag present data state
current co-prescrib requir va vt az ri fl wa ca start
soon note patient mme opioid dose threshold
fill naloxon prescript versu nation fell well short fda
long-run estim panelist fda present note
discrep continu agenc would need take step increas adopt
narcan account naloxon prescript fill base data
present compani believ product capac
carton dose per year expect increas carton
dose would evalu ad addit capac respons increas
demand file adapt pharma financi follow acquisit report
net product revenu
iqvia cowen compani
busi fill/finish busi produc revenu
ramp manag indic expect continu
expand capac busi beyond receiv ciadm
design allow surg capac manufactur product emerg
medic need barda send compani need contract manufactur
aid emerg believ collabor provid busi
develop lead june announc expans camden
fill/finish facil locat baltimor md expect complet
expect revenu busi acquisit paxvax
includ manufactur facil near bern switzerland manag believ
allow compani better attract european client
make progress toward long-term goal emerg financi goal call
total revenu revenu outsid us net expens
net revenu sg expens total revenu addit
compani increas target non-gaap net incom revenu result
favor tax rate chang manag look attain goal
increas product sale grant contract revenu busi
revenu emerg expand intern sale forc increas
sg work includ product advanc develop increas
expenditur develop pipelin product outsid contract-driven work
invest thesi view lead biodefens contractor
grow non-biodefens portfolio fda approv build late increas
biothrax product capac howev follow-on govern contract
smaller anticip place biothrax growth prospect risk
manag emphas intent grow revenu earn organ
well acquisit
look clariti nuthrax develop manufactur valid
phase studi initi updat short long-term prospect narcan
biothrax raxibacumab vaxchora vivotif well busi
cowen compani
datestagemilestonebiothrax deliveri updatesnuthrax emerg use author iiiiniti follow-on contract us govflu-igiv iistudi completionzika-ig zika therapeut itrial zika vaccin iful phase data cowen
strong demand favor price continu drive growth
cometriq market fulli penetr time
expect total revenu exceed expect
street consensu bloomberg cowen compani
focu investor
earn summari report strong revenu
q/q expect cabo sale slightli decreas driven expect season
scrip q/q first two month slow sinc expans
first-lin rcc decemb novemb partner ipsen receiv approv
european commiss ec cabometyx member state
european union norway iceland believ cabo achiev rcc
sale support stock valu pdufa cabometyx set
high likelihood approv us
confer call topic topic discuss compani call like
includ possibl approv cabometyx us market adopt
eu continu adopt rcc updat clinic progress cabo
endocrin tumor differenti thyroid cancer radioiodine-
refractori differenti thyroid carcinoma dtc discuss on-going cotel
combin trial braf-wt braf-mut melanoma
respect partner roch overview data
celesti updat newli initi
cabometyx sale commerci two formul cabozantinib tablet
formul brand cabometyx treatment advanc rcc capsul
formul brand cometriq approv medullari thyroid cancer mtc physician
recept toward cabometyx strong consult increasingli view
cabometyx best overal profil tki rcc
cabometyx consensu expect call q/q sale
recal cabometyx sale fell short expect
sale neg impact week wholesal inventori draw
q/q impact higher gross-to-net discount g-to-n vs
manag attribut higher g-to-n discount inventori channel
year-end adjust impact includ reset donut-hol
medicar part patient reset commerci co-pay assist plan
privat plan believ adjust fulli mask compani
donut-hol headwind seen g-to-n anticip lower
cowen compani iqvia
inflect cabo demand appear driven decemb label expans
treatment patient first-lin advanc rcc believ cabo
potenti rcc market market dynam competit
bristol myer opdivo yervoy io io combin therapi expect captur
major first-lin share consult envis cabometyx use patient
dont toler io therapi also expect cabometyx benefit opdivo exit
second-lin market provid cabo room move
continu develop cabozantinib addit oncolog indic effort
broaden drug franchis clinicaltri gov indic
cabozantinib clinic trial on-going sponsor outsid rcc mtc
sever trial studi cabozantinib combin io agent
bmi nivolumab roch atezolizumab decemb announc
initi phase pivot trial cabometyx combin
atezolizumab tecentriq versu sorafenib previous untreat advanc
hepatocellular carcinoma co-primari endpoint trial progression-
free surviv overal surviv exploratori arm also evalu cabozantinib
monotherapi first-lin set
partner ipsen takeda ex-u metyx approv rcc
europ septemb februari struck deal ipsen
cabo ex-u /ex-japan right ipsen launch cabometyx eu well
nordic countri austria netherland addit reimburs
discuss progress ipsen sale euro obtain
royalti march chmp grant partner ipsen applic
cabometyx first-lin advanc rcc posit opinion
earli partner cabo takeda japan receiv
up-front payment elig potenti develop regulatori
first-sal mileston well tier royalti first
cabo sale follow royalti takeda begun phase ii bridg studi
cabo support regulatori file japan
cometriq sale mtc repres small opportun cometriq given estim
patient affect off-label use rcc cometriq
declin demand revert back level consist nearli fulli
penetr mtc market sale flat q/q believ
drug remain low interest investor
digit ex-u royalti cotel roch mek inhibitor approv combin
zelboraf braf mutant-posit unresect metastat melanoma given profit
share natur collabor modest opportun melanoma
dont expect meaning revenu near term cotel sale
multipl cotel combin therapi develop roch put much focu
develop cotel combin agent includ inhibitor
tecentriq atezolizumab avastin roche/abbvi venclexta clinicaltri gov list
on-going studi variou cotel combin studi solid liquid
preclin combin inhibit gain support data show
mek inhibit lead upregul mhc-i molecul tumor cell increas intra-
tumor cell infiltr enhanc efficaci phase ib data patient
metastat colorect cancer provid support cobimetinib atezolziumab
clinic activ patient refractori immun therapi asco-gi januari
phase trial show combin associ orr pr
patient microsatellit stabil receiv
prior therapi respond patient local report microsatellit
stabil one low microsatellit instabl three unknown microsatellit
instabl comparison phase ii trial microsatellit stabl refractori colorect
cancer patient treat pembrolizumab zero patient respond therefor
believ respons seen cobimetinib/atezolizumab may driven
combin rather sole backbon
phase trial evalu cobi atezolizumab wild type braf metastat
melanoma phase trilog trial cobi atezolizumab vemurafenib combin
treatment-nav mutation-posit patient advanc melanoma
also way trilog initi base posit phase data orr
includ cr rate
invest thesi believ cabo potenti rcc includ modest sale
potenti rcc also succeed pivot trial snda
submit march partner ipsen applic valid ema march
indic could add sever hundr million dollar revenu also hold
substanti ownership profit share low doubl digit ex-u royalti
roch cotel cobimetinib mek inhibitor approv combin
vemurafenib b-raf mutant melanoma patient cotel commerci
opportun set modest drug develop multipl
indic combin studi includ phase combo trial atezolizumab
colorect cancer
cowen vs street consensu estim
think estim consensu appear achiev given
 prescript trend hiv franchis q/q biktarvi
launch well q/q
analysi suggest estim consensu may slightli
low given moder declin q/q prescript
consensu assum patient treat equat
per certifi center consist treatment rate
appear reason
moder upsid hiv hcv franchis could yield
total revenu line estim
estim consensu appear achiev given strong
launch biktarvi
expect declin hcv revenu begin moder
focu investor rel small impact
total revenu ep
anticip gild revenu grow y/i
first time sinc
project ep trough consensu
impli year modest declin
street consensu hiv/hbv sale hcv sale yescarta revenu total revenu pro forma ep ep bloomberg
cowen compani
report date monday februari gilead host confer call et
code
earn comment overal expect solid quarter gilead potenti moder
upsid hiv hcv franchis could yield total revenu non-gaap ep
line estim consensu biktarvi third full quarter sale
 provid boost hiv franchis scrip suggest upsid
consensu scrip gilead hcv franchis q/q continu wane
declin appear moder base physician check hope
hcv revenu stabil next quarter launch
biktarvi hiv reinvigor growth franchis expect result
phase trial filgotinib finch finch studi ra selonsertib
stellar trial nash optimist filgotinib cautiou
selonsertib investor success selonsertib would surpris
investor add anoth franchis catalyst share overal financi
return growth pipelin bear fruit optimist gilead stock
outperform
driven strong launch biktarvi world-wide hiv estim
q/q y/i consensu approxim q/q
y/i estim includ sale q/q y/i ex-u
sale q/q y/i analysi suggest gilead hiv revenu
track somewhat world-wide hiv revenu estim
 hiv franchis sale estim includ project viread vemlidi emtriva
symtuza vitekta gilead indic hiv franchis
sale flow privat pay channel track iqvia
sale reimburs public payor includ state adap program veteran
administr public health system therefor one must care
predict quarterli result much certainti iqvia prescript data
sale government-reimburs channel track iqvia
nonetheless iqvia data best sourc inform access
therefor acknowledg caveat inform compar current
scrip trend estim
 number incorpor viread/vemlidi sale estim
q/q follow launch viread gener late viread trx
q/q combin viread/vemlidi prescript q/q take
scrip trend account viread/vemlidi track toward revenu
 truvada/descovi estim flat q/q
truvada/descovi scrip q/q impli revenu
 atripla estim q/q atripla scrip
q/q impli atripla revenu track toward
complera/odefsey estim q/q iqvia-report
complera/odefsey prescript q/q impli combin revenu
approxim stribild/genvoya/biktarvi estim
q/q combin growth prescript impli combin revenu
estim scrip modest think estim reason
altogeth iqvia prescript trend suggest hiv franchis sale
approxim q/q estim q/q
total hiv franchis growth rapid growth biktarvi prescript
q/q made declin prescript tdf-contain
regimen total iqvia-report prescript gild hiv franchis grew
iqvia cowen compani
ex-u hiv franchis ex-u hiv franchis estim q/q
y/i vs notabl first gener viread truvada
atripla enter eu market juli rather steep revenu declin start
anticip launch biktarvi addit european countri
help off-set impact gener late without scrip data visibl
ex-u sale low nonetheless think estim appear reason
take account prescript trend ex-u sale think
world-wide hiv estim q/q y/i consensu
q/q y/i achiev could low
world-wide hcv franchis revenu estim q/q y/i
slightli street consensu q/q y/i estim includ
 sale q/q y/i eu sale q/q
y/i intern sale q/q y/i overal
estim consensu appear somewhat conserv given moder declin
hcv scrip overal gilead franchis
unit state iqvia record harvoni trx q/q
nrx q/q iqvia record epclusa trx q/q nrx
q/q iqvia record vosevi scrip q/q nrx q/q
iqvia-record sovaldi prescript nrx altogeth iqvia
record gilead hcv franchis q/q nrx q/q
iqvia health cowen compani
 hcv market q/q therefor major
declin gilead prescript due declin overal treatment volum
though due share loss follow launch mavyret
q/q gilead trx share declin last week
last week last week last
week increas modestli last week abbvi
share increas period
abbvi share gain appear moder base commentari
therapeut confer last octob expert expect littl chang patient volum
compar anticip volum continu declin thereaft
physician report reimburs longer obstacl treatment
regimen chosen base insur coverag given similar efficaci
conveni price physician anticip gilead regimen
captur approxim equal share hcv market given commentari
hope declin gilead franchis moder next quarter
gilead report harvoni revenu epclusa revenu
 vosevi revenu therefor iqvia prescript trend
would impli harvoni sale q/q epclusa sale
q/q vosevi sale q/q
togeth figur suggest total hcv franchis revenu
q/q would q/q y/i
iqvia health cowen compani
gilead previous suggest price per patient genotyp
converg price week genotyp patient due competit
mavyret mavyret price monthli wac would impli
averag net price per patient gilead report treat
patient total hcv revenu impli averag net
price per patient impli price discount wac
week cours mavyret gilead suggest averag net price
stabil expect net price rel flat q/q septemb gilead
announc newli launch subsidiari begin offer
author gener epclusa harvoni januari gilead expect
gener reduc patient cost expand access gilead indic list
price author gener gener epclusa
gener harvoni compar net price brand version
given decreas sale volum wholesal would need keep less inventori
channel assum maintain two week inventori would
approxim inventori channel end would
need inventori end suggest reduct
channel inventori could also reduc report revenu approxim
overal analysi suggest hcv revenu q/q y/i
impli hcv revenu could beat estim q/q
y/i
outsid harvoni record ex-u sale q/q
y/i epclusa ex-u sale q/q y/i vosevi
ex-u revenu q/q total ex-u hcv sale q/q
y/i gilead note number new patient start intern market
total ex-u hcv estim
without prescript data limit visibl eu trend q/q declin
project reflect continu declin patient volum earli launch
bolu continu subsid well impact abbv mavyret overal
project chang price share outsid approxim
magnitud think reason assumpt
overal analysi impli world-wide hcv franchis revenu estim
q/q y/i street consensu q/q y/i
may somewhat low nonetheless find difficult much convict
report given lack visibl trend price ex-u util
yescarta project yescarta revenu q/q consensu
q/q consensu suggest yescarta account
gilead revenu perform meaning impact gild
 nonetheless gilead pay acquir kite yescarta
perform like outsiz impact sentiment toward gilead stock
gilead disclos treatment center certifi prescrib yescarta
octob last year end june new center continu
author gilead indic focu shift increas patient flow
gilead anticip adopt gradual improv center gain experi
yescarta approv eu august gilead previous indic
plan author center europ end initi focu
would launch germani franc
yescarta list price per patient consensu estim would suggest
patient treat yescarta estim would impli
consensu estim would translat patient treat per certifi
estim consensu consist pace would
appear reason though visibl low
geograph distribut product sale gilead product sale
 europ intern
oper expens total oper expens estim q/q
y/i project non-gaap gross margin estim non-gaap
expens revenu q/q y/i project non-gaap sg
revenu q/q y/i
tax rate model assum tax rate gilead updat guidanc
non-gaap effect tax rate includ impact
tax rate due favor tax settlement
ep non- ep estim q/q y/i estim
q/q bloomberg consensu call non-gaap ep
q/q y/i ep q/q
guidanc perhap even import financi guidanc
investor look sign trough earn past particular
worst declin gilead hcv franchis
estim call world-wide hcv revenu y/i
hiv franchis sale y/i yescarta sale y/i
total revenu y/i forma ep y/i bloomberg
consensu hcv sale approxim y/i hiv sale
approxim y/i yescarta revenu y/i total
revenu y/i non-gaap ep y/i gilead
provid guidanc hcv product sale non-hcv product sale gross margin
expens sg expens tax rate impact non-cash charg
septemb gilead galapago announc posit result filgotinib
trial ra patient inadequ respons biolog dmard
trial enrol difficult treat popul think de-risk filgotinib
trial therefor optimist success
enrol ra patient inadequ respons methotrex
patient requir stabl dose methotrex least swollen
tender joint screen baselin patient random receiv
placebo humira filgotinib filgotinib week primari
endpoint trial proport patient achiev week
secondari endpoint includ radiograph progress mtss
patient report outcom filgotinib evalu superior placebo
humira
enrol ra patient nave methotrex therapi patient
requir least swollen tender joint screen baselin
patient random receiv methotrex filgotinib methotrex
filgotinib methotrex filgotinib week primari
endpoint trial proport patient achiev week
secondari endpoint includ radiograph progress mtss
simtuzumab /- selonsertib nash aasld trial
conduct simtuzumab separ shown inact nash therefor
trial becam de facto placebo control trial selonsertib manag
present data base selonsertib dose selonsertib vs
selonsertib vs simtuzumab monotherapi analysi
simtuzumab monotherapi patient experienc stage greater improv
fibrosi selonsertib produc dose-depend increas efficaci
patient patient least stage improv fibrosi
similarli simtuzumab patient progress cirrhosi compar
patient selonsertib patient selonsertib
base upon data gilead initi phase trial selonsertib nash februari
stellar trial enrol nash patient fibrosi receiv
placebo selonsertib week primari endpoint
trial proport patient achiev least stage improv
fibrosi worsen nash week data expect
stellar trial ident design except enrol patient fibrosi
baselin data stellar expect
cowen compani confer
cowen compani confer
specialist poll cowen confer gave gilead
selonsertib stellar phase trial patient chanc succeed
even slightli less optimist parallel stellar phase trial patient
panelist agre stellar better odd success suggest view
much harder revers stage fibrosi particularli given hard
know long patient live stage diseas therefor
degre qualiti scar organ howev one panelist also note
see mechan good anti-fibrot potenti like combin well
compound panelist agre far like drug safeti
profil though note would like cautiou prescrib cirrhot
patient given safeti issu seen phase
opinion investor expect success stellar similarli low
therefor hit primari endpoint could meaning catalyst gilead
would add anoth promis pipelin program diseas
current recogn revenu
thesi investor wait gilead revenu stabil two
year declin despit continu hcv contract model suggest trough
gilead total revenu may reach project non-
gaap ep non-gaap ep grow compound-annual-growth-rate
high growth compound-annual-growth-rate nonetheless better relentless declin
past coupl year continu believ gilead under-valued cash flow
dcf-base price target remain
look data selonsertib phase studi
nash stellar data filgotinib phase finch finch studi ra
stubq cowen vs street consensu estim gwph
epidiolex launch novemb
focu investor
focu investor
estim assum patient w/w therapi
focu investor
focu investor
cowen compani bloomberg consensu
earn comment focu gw earn report almost sole
epidiolex perform sinc novemb launch consult
enthusiast epidiolex therefor expect launch rapid
nonetheless gw suggest could take sever week patient secur
reimburs earli launch anticip modest revenu
decemb quarter believ investor expect similarli low though
good consensu number avail gw process transit
septemb fiscal year end calendar year report therefor quarter end
decemb stub quarter consensu reflect stub quarter
rather unclear accur current consensu suspect
number could reflect mixtur stub quarter nonetheless
avail figur suggest consensu around base enthusiasm
consult think achiev though admittedli reimburs like
gate factor epidiolex success earli stage launch
receiv fda approv treatment seizur associ lennox-gastaut
syndrom dravet syndrom patient least year age cbd
schedul control substanc need reschedul prior launch late
septemb reschedul epidiolex schedul least restrict schedul
enabl readi access epilepsi patient addit reschedul
feder level state washington also reschedul epidiolex
sale organ activ work educ physician gw estim
target physician cover thu far though launch still
earli manag character demand healthi strong uptak
pediatr neurologist epileptologist particular gw suspect pediatr
specialist may familiar therefor adept prescrib weight-
base titrat drug like epidiolex adopt among adult epileptologist may
take somewhat longer prescript reimburs govern
commerci plan sever plan establish coverag epidiolex includ
express script cover million live million million
epidiolex includ prefer brand nation formulari prior
author requir five largest payor four initi coverag
epidiolex prior author indic term public payor ff
medicaid manag medicaid state initi coverag
earn call novemb gw reiter initi primari focu
ensur new patient access epidiolex patient expand
access open-label extens program transit clinic
commerci product around epidiolex avail earli novemb
take coupl week patient secur reimburs gwph
suggest epidiolex revenu decemb quarter rel modest
begin ramp earnest expect initi epidiolex sale reflect mostli
prescript patient dravet lg use among patient
primari diagnosi dravet lg ramp time continu expect
epidiolex see signific use wide varieti refractori epilepsi
epidiolex file ema gw optimist posit decis
prepar commerci launch major european market
underway manag guid well prepar term manufactur
capac meet anticip demand europ gw plan launch
epidiolex addit european countri
physician consult think epidiolex demonstr efficaci benign side
effect profil drive wide adopt among refractori efficaci patient
 epidiolex estim
respect notabl estim assum refractori
pediatr epilepsi patient therapi continu think gw
under-valued epidiolex potenti
invest thesi gw epilepsi program major driver valu stock
recent approv epidiolex oral liquid formul highli purifi extract
cbd demonstr compel efficaci multipl intract form epilepsi
dravet lg follow reschedul end septemb epidiolex
launch novemb believ epidiolex broadli use
across refractori epilepsi off-label support global sale
look ema approv decis epidiolex fda meet outcom
develop plan sativex ms spastic initi open-label studi cbdv
rett syndrom autism
pre-announce aloxi gener arbitrag
anticip continu
pre-announce launch jan
emend gener arbitrag anticip sept
focu investor
cowen compani consensu thomson reuter
earn summari heron report revenu cinv franchis
sustol cinvanti beat guidanc franchis
previous beat guidanc well compani also issu cinv revenu
guidanc view appropri conserv light
extend aloxi gener arbitrag potenti emend iv gener
arbitrag revenu suppress ep major
focu investor although estim in-lin consensu
heron end cash/equival short-term invest
believ compani suffici capit reach key mileston
includ approv commerci launch
cinv franchis pois strong growth august fda approv sustol
first extended-releas receptor antagonist prevent acut
delay nausea vomit associ moder emetogen
chemotherapi anthracyclin cyclophosphamid combin
chemotherapi regimen ac-bas regimen specif sustol brand
inject class obtain indic delay ac-bas regimen one
commonli prescrib highli emetogen chemotherapi regimen hec
sustol closest competitor eisai aloxi lack label delay hec aloxi
current market leader gener sale annual demand
estim unit importantli teva announc launch gener version
aloxi march sever formul launch well
result monthli aloxi sale record iqvia come believ
dynam leav sustol posit prefer drug out-pati set
medicar part-b reimburs mechan heron took price increas sustol
decemb wac per pre-filled syring versu aloxi
wac per vial repres premium short term anticip
weak sustol due increas discount compet aloxi
gener physician abl use gener aloxi receiv reimburs
histor brand aloxi price start believ sustol begin
take market share aloxi initi pressur aloxi gener pass
also believ even add asp reduc incent doc
use sustol remain heron collect addit data order demonstr
sustol benefit aloxi background antagonist dexamethason
common triplet combo patient receiv sustol requir hydrat versu
aloxi final sustol receiv perman j-code januari
streamlin reimburs
iqvia cowen compani
drive cinv franchis heron launch cinvanti januari
wac januari cinvanti heron
formul aprepit antagonist lack surfact polysorb
formul associ fewer teae compar current
market leader emend iv addit compani present data indic
minut iv push cinvanti similar safeti profil compar standard
minut infus compani plan seek addit label data
believ ad flexibl help drive adopt januari tesaro publish
dear provid dhcp letter regard seriou advers reaction
inject emuls varubi specif letter discuss seriou hypersensit
reaction includ anaphylaxi anaphylact shock requir hospit
reaction occur soon infus varubi within first
minut administr normal given minut session tesaro
subsequ suspend distribut varubi iv februari subsequ
divest asset tersera plu mileston oral varubi still
avail see competitor heron iv product strongli
prefer cinv captur market
iqvia cowen compani
cinvanti complementari product sustol target major pathway
underli cinv two drug frequent administ patient
highli concentr natur prescrib practic also assist market
cinvanti sale rep introduct practic alreadi occur mani case
januari compani note signific underutil antagonist hec
patient heron previous report approxim patient
hec regiment receiv therapi despit nccn guidelin recommend use
patient regimen receiv suggest even larger market
opportun hrtx cinv franchis suggest current market leader aloxi
emend iv
base factor compani rais sale guidanc cinv
franchis beat pre-announce
revenu remind heron also increas sustol guidanc mid-
year beat street consensu franchis ahead
pre-announce consensu month ago includ
sustol plu cinvanti rate sustol
cinvanti take market share aloxi emend gener respect
key determin cinv franchis later
demonstr best-in-class profil post-op pain pdufa april
expect investor primarili focus heron pain franchis drug
candid heron phase pain drug combin bupivacain
meloxicam biochronom delay releas formul
grant fast-track design post-op pain local administr phase
studi post-op pain report posit top-lin data march
studi show provid superior pain control compar
gener bupivacain clear separ pain score hour
bunionectomi hour hernia repair addit significantli fewer patient
requir opioid rescu medic addit phase iib trial report posit data
june tka breast augment compani nda accept
assign pdufa date april see littl regulatori risk allow
commerci guid heron follow strong uptak driven
physician desir reduc opioid use post-op set opioid spare
compar activ control arm benefici note heron
collect opioid-spar data month believ carri weight
physician fda compar current data compani also
propos standard protocol outpati open hernia repair surgeri
reduc amount opioid would prescrib compani suggest
prescrib opioid patient experienc pain score
patient pain score time heron estim would
elimin opioid prescript patient base multimod therapi
compani believ pill oxycodon would suffici avoid callback
mani case compar pill prescript common patient step
nsaid thereaft found effect wide implement believ
protocol would look favor fda closest brand
competitor pacira exparel current approv long-act version bupivacain
without meloxicam anti-inflammatori compon believ
investor look exparel sale pacira pre-announce sale
refer potenti howev view develop
program give import advantag exparel specif compar arm
gener bupivacain efficaci hour posit best-in-
heron also disclos second extend durat local anesthet current
preclin develop pig post-operative pain model demonstr pain control
day compar favor liposom bupivacain salin
pig model detail formul mechan action improv
disclos compani plan initi phase ii trial
cowen compani
invest thesi heron commerci biotechnolog compani
use proprietari biochronom polymer-bas drug deliveri platform improv
therapeut profil inject pharmaceut control drug releas
extend durat action heron two approv drug chemotherapi
induc nausea vomit sustol cinvanti believ primari valu
pain drug complet multipl phase ii studi well pivot
phase trial consist show strong result believ
best-in-class opioid altern come ideal time medic
commun move away opioid post-surg pain manag
cowen vs street consensu estim
quarterli financi like key investor focu prior
sacituzumab launch
oncolog launch tend rapid though immu
fiscal year end abil sacituzumab
hit consensu depend time
cowen compani bloomberg consensu
final countdown month regulatori specul follow year decad
develop culmin sacituzumab pdufa date januari
treatment line metastat tripl neg breast cancer tnbc remain
hope approv around pdufa date
follow disclosur issu review confer call last fall
